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ABSTRACT OF THE DISSERTATION 
 
The Intestinal Gut Microbiome as a Biomarker and 
Driver of Obesity and Non-Alcoholic Fatty Liver Disease 
by 
Tien Sy Dong 
Doctor of Philosophy in Molecular, Cellular, and Integrative Physiology 
University of California, Los Angeles, 2020 
Professor Joseph R. Pisegna Committee Co-Chair 
Professor Jonathan P. Jacobs Committee Co-Chair 
Nonalcoholic fatty liver disease (NAFLD) affects almost 1 out of every 5 Americans. The 
development of NAFLD increases an individual’s risk for cardiovascular disease, cirrhosis, and 
cancer. Given that there are few treatments available for NALFD, it is imperative to understand 
the features that can prognosticate and alter the progression of NAFLD. One area of research that 
has gained significant traction is the role of the gut microbiome in the development and progression 
of NAFLD. By utilizing a multi’omics approach, we discovered that the gut microbiome can affect 
obesity through alterations of the brain-gut axis. In a study of over 100 patients, we saw that the 
gut microbiome was highly associated to food addiction. Patients with food addiction had 
significantly lower abundances of Bacteroides, Akkermansia, and Eubacterium, and a higher 
abundance of Megamonas. This was associated with a reduction in a neuroprotective tryptophan-
related metabolite, indolepropionate, and altered connectivity in the brain’s reward regions. This 
 iii 
data suggests that the gut microbiome plays a role in eating behavior and is likely a modifiable 
risk factor for obesity. Furthermore, research has shown that the microbiome and metabolite profile 
of patients with NAFLD differs at each stage of the disease. Using a machine learning algorithm, 
we created and validated a classifier based on the gut microbiome that highly predicts advanced 
fibrosis in patients with NAFLD. To explore the causal effects of the gut microbiome on the 
development of NAFLD, we utilized the microbiome of bariatric surgery patients and transplanted 
them into antibiotic treated mice. Through this model, we see that an obese phenotype microbiome 
is able to induce significant weight gain and hepatic steatosis. Associated with these changes we 
see a significant alteration of the expression levels of natural killer T-cells, cytotoxic T-cells, 
Kupffer cells, and monocyte-derived macrophages. The data shows that not only can the gut 
microbiome prognosticate NAFLD, it can also alter the progression of NAFLD through changes 
of the innate immune system of the liver. This work shows the feasibility of the gut microbiome 
both as a biomarker but also as a source for potential novel therapeutics against obesity and 
NAFLD.   
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Chapter 1 
The Modern  Landscape of Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome 
2 
 
INTRODUCTION 
The human microbiome represents all microorganisms residing on or within the human 
body, including bacteria, archaea, fungi, protozoans, and viruses. The human microbiome has as 
the same number of cells and about 100 times more genes than the human body.1–3 These genes 
encode a wide array of pathways that produce bioactive molecules that are derived from dietary or 
metabolic precursors.4 While one of the main function of the gut microbiome is the fermentation 
and energy extraction of indigestible dietary fiber, many studies have connected the microbiome 
and its metabolites to the development of certain diseases such as obesity, metabolic syndrome, 
and nonalcoholic fatty liver disease (NAFLD).5 
The incidence of NAFLD is rapidly growing in conjunction with the epidemic of obesity 
and metabolic disorders.6 The risk factors associated with NAFLD include central obesity, insulin 
resistance, hyperlipidemia and metabolic syndrome.  Data has suggested that NAFLD is more 
prevalent in men as compared to women and more prevalent in patients with Asian or Hispanic 
heritage.7,8 NAFLD is now the one of the most common causes of chronic liver disease in the 
Western world and the top two reasons for cirrhosis and liver transplantation.9,10 NAFLD is a term 
that encompasses two distinct diseases: nonalcoholic fatty liver (NAFL) and nonalcoholic 
steatohepatitis (NASH). While patients with NAFL have only bland steatosis on liver biopsy, 
patients with NASH will also have lobular inflammation and/or hepatocyte ballooning, a sign of 
hepatocyte damage. Patients with NAFL will often remain stable for many years and will rarely 
ever progress further.11,12 Patients with NASH, however, are more likely to progress to fibrosis, 
cirrhosis, and hepatocellular carcinoma.11,13 Prior epidemiological studies have shown that patients 
with metabolic syndrome and insulin resistance were more likely to develop NASH than NAFL, 
and therefore are more likely to experience worse outcomes.14 Because of the interplay between 
 3 
the microbiome and energy metabolism, there have been many recent research studies that have 
looked into the relationship between the human microbiome and NAFLD development and 
progression. 
In this chapter we will explore how diets associated with obesity and NAFLD affect the 
microbiome and how the microbiome in turn can influence the pathogenesis of these diseases. We 
will also review potential mechanisms and pathways that link the microbiome to the development 
and progression of NAFLD. Finally, we will discuss limitations of current research and explore 
potential future directions including therapeutic applications. 
METHODS 
A comprehensive literature review was performed from 1995 to the present using the 
following key terms in PubMed: Nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, 
cirrhosis, fibrosis, obesity, metabolic syndrome, diabetes, fat, adipose, bacteria, and microbiome. 
Emphasis was given for articles published within the last 5 years. 
DIET AND THE MICROBIOME 
Diet plays a critical role in the development of obesity, metabolic syndrome, and NAFLD. 
Epidemiological studies have consistently shown associations of diets high in fat and refined 
sugars with the incidence of obesity and NAFLD.15 In experimental models, such diets have been 
shown to increase adiposity, hepatic steatosis, and inflammation.16 Here we will discuss how the 
diets most commonly associated with NAFLD and obesity affect the gut microbiome. 
Western Diet. A Western diet is often defined as a diet that is high in sugar, fat, processed meats, 
simple grains, while being low in fiber.17 It has been linked to many negative health outcomes such 
as obesity, insulin resistance, metabolic syndrome, and NAFLD.17,18 Studies have shown that a 
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Western diet can affect many different cells including endocrine cells, adipocytes, and hepatocytes. 
However, there is also a growing body of evidence that links the negative effects of a Western diet 
to changes in the microbiome.17 Patients on this diet will often have a significantly lower microbial 
diversity and species richness than those on a more agrarian diet, features that are often associated 
with gut dysbiosis.19 The Western diet microbiome is often described as having a higher abundance 
of Firmicutes with a relatively lower abundance of Bacteroidetes.20 The high Firmicutes to 
Bacteroides ratio decreases in subjects who lose weight on either a carbohydrate-restricted or fat-
restricted diet.21 Ways by which the microbiome can cause metabolic changes in the host includes 
changes in short-chain fatty acid production, alterations in gut hormones like peptide YY and 
glucagon-like peptide, and activation of toll-like receptor signaling through the production of 
lipopolysaccharides or endotoxins. 22 At a genus level, a Western diet is associated with depletion 
of Bifidobacterium and Lactobacillus and enrichment of Enterobacter.23 The role of the 
microbiome in mediating the link between a Western diet and obesity has been examined 
extensively in several mice models. Colonization of germ-free mice with the microbiota of obese 
mice (induced by leptin-deficiency or a Western diet) results in increased body fat accumulation 
compared to colonization with microbiota from lean controls.24,25 Similarly, germ-free mice 
colonized with feces from obese humans had increased adiposity on a high fat diet compared to 
germ-free mice colonized with feces from lean humans in weight discordant twin pairs.26 
Moreover, mice deficient in Toll-like receptor 5 and inflammasome components develop 
susceptibility to Western diet-induced obesity that can be transmitted to other mice by fecal 
transplantation.26 
High Saturated Fat. Similar to the Western diet, diets high in saturated fats can also have 
deleterious effects on health and the microbiome.  Epidemiological studies have shown that diets 
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that are high in saturated and trans-fat are associated with obesity, cardiovascular disease, and 
NAFLD.27,28 Mice that are fed a diet high in saturated fat develop similar hepatic steatosis and 
inflammation as seen in patients with NAFLD.28 However, not all fats have similar results. Diets 
high in polyunsaturated fats, such as those seen in a Mediterranean diet, have been associated with 
reduced cardiovascular events and a lower prevalence of obesity.26–28 To examine the role of 
different fats on the microbiome, one study of 88 patients with risk factors for metabolic syndrome 
were fed either saturated or monosaturated fats.32 The authors found that a diet high in saturated 
fats led to a reduction of bacterial species richness and an overabundance of Faecalibacterium 
prausnitzii, changes that were not seen in patients taking monounsaturated fats.32 However, this 
association with F. prausnitzii should not be construed as negative since the introduction of F. 
prausnitzii was protective against hepatic steatosis and adipose tissue inflammation in mice fed a 
high fat diet.33 In one of the largest study examining the role of saturated and polyunsaturated fats, 
Menni et al demonstrated in 876 women that a diet higher in polyunsaturated fats were associated 
with a higher microbial diversity that was predominated by members of the Lachnospiraceae 
family.34 These findings suggest that the specific composition of fat may be more critical than the 
total amount of fat. This idea is corroborated in a recent animal study. Mice that were fed on a lard 
fat diet had a greater abundance of Bacteroides and Bilophila, and a lower abundance of 
Lactobacillus and Akkermansia.35 Mice on a lard fat diet also had higher toll-like receptor 
signaling, white adipocyte inflammation, and insulin resistance as compared to mice fed on a fish-
oil based diet.35 The fecal transplantation of the lard fat-associated microbiome into germ-free 
animals was able to replicate the donor’s metabolic phenotype, suggesting that these pathways are 
in part mediated by the microbiome.35 
ROLE OF THE MICROBIOME IN OBESITY AND INSULIN RESISTANCE 
 6 
One of the early pivotal studies that linked the microbiome to the development of obesity 
came from Turnbaugh et al. in 2006.24 They used 16s rRNA sequencing to demonstrate an 
increased ratio of Firmicutes to Bacteroidetes in obese humans and experimental mice on a high 
fat diet, and found that colonization of germ-free mice with this obesity-associated microbial 
profile could induce an obese phenotype in their germ-free animals. Since then, several other 
studies have shown that the microbiome was able to influence weight gain by affecting host gene 
expression, metabolic pathways, and even the gut-brain-axis.36–39 These pathways include short-
chain fatty acid signaling and lipopolysaccharide activation of toll-like receptors.40 All of which 
can lead to altered gene expression, hormone secretion, and energy consumption in adipocytes and 
eventual changes in host metabolism.40 Additionally, several papers have shown that the efficacy 
of surgical weight loss interventions may be in part mediated by shifts in the gut microbiome.41 
For example, a study in mice found that gastric bypass led to a persistent increase in Escherichia 
and Akkermansia, and that the microbial transplant from these mice into non-operated germ-free 
mice successfully transferred the donor phenotype.42 
While obesity is a major risk factor for the development of NAFLD, another major risk 
factor is insulin resistance. As such a small double blind randomized trial was performed to 
examine the effects of probiotics and metformin on patients with NASH.43 Sixty-four NASH 
patients were randomized to either a commercially available probiotic mixture with metformin or 
metformin alone for 6 months. The author showed that the addition of a probiotic led to a 
significantly greater reduction in serum liver enzymes and hepatic steatosis as determined by 
ultrasound. Similarly, another randomized control trial with 66 NASH patients showed that the 
oral supplementation with Bifidobacterium longum improved both liver enzymes and insulin 
resistance metrics.44 This association between the microbiome and insulin resistance led Wu et al 
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to examine the effects of metformin on the microbiome of diabetic patients.45 They found that not 
only does metformin greatly alters the microbiome, some of metformin’s effects on the host was 
recapitulated by transferring this altered microbiome into germ-free animals. Wu’s and prior 
studies provide support that the microbiome may play a role in insulin sensitivity and demonstrates 
how the microbiome can potentially alter the course of NAFLD through related pathways. 
MICROBIOME ASSOCIATIONS ACROSS THE SPECTRUM OF NALFD 
The growing evidence linking the microbiome to obesity spurred interest in the potential 
role of the microbiome in other metabolic diseases including NAFLD. Here we will review 
evidence from human studies for microbiome associations with NAFL, NASH, and NAFLD-
related advanced fibrosis. 
NAFL. Studies that have examined the microbiome profile of patients with NAFL as compared to 
either healthy controls or weight-matched controls have yielded variable results. Pediatric NAFL 
patients have been reported to have more Prevotella and less Oscillospira than matched 
controls.46–48 In studies of adult NAFL patients, Lactobacillus and Escherichia have been enriched 
while Coprococcus and Prevotella have been depleted (Table 1-1).49–52 These studies utilized 16s 
rRNA sequencing, which can only provide insight into composition (what bacteria are there) but 
not function (what products are made by bacteria that may affect disease). Three studies took a 
multi’omics approach combining microbiome sequencing with metabolomics analysis to evaluate 
potential microbial metabolic pathways promoting the development of NAFL.51–53 Raman et al 
found 18 differentially abundant stool metabolites associated with NAFL in adults, including 
elevated levels of derivatives of butanoic, propanoic, and acetic acid.53 Similarly, Da Silva et al 
found enrichment of propionate and isobutyric acid in the feces of NAFL patients.51 These 
differences were associated with an increase in serum 2-hydroxybutyrate and L-lactic acid. The 
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most convincing data to date that links the microbiome to the development of NAFL comes from 
Hoyles et al.52 This study assessed the hepatic transcriptome, gut metagenome, along with serum 
and urine metabolome of a cohort of non-diabetic obese women. NAFL was associated with 
increased serum levels of several branched-chain and aromatic compounds. Administration of one 
of these, phenylacetic acid, to mice colonized with human fecal microbiota triggered hepatic 
steatosis. 
NASH. Studies characterizing the microbiome profile of NASH compared to NAFL or obese 
controls have found more consistent differences than has been seen for NAFL; however, there is 
still variability in the findings.54 In children, patients with NASH generally had more 
Ruminococcus, Dorea, Streptococcus and Escherichia as compared to their obese counterparts.46–
48,55 In adults, patients with NASH had lower levels of Faecalibacterium, Ruminococcus and 
Bifidobacterium51,56 and a higher level of Lactobacillus.57 Few studies have examined fecal or 
serum metabolites distinguishing NASH from simple NAFL, most likely due to the fact that a 
diagnosis of NASH often requires a liver biopsy in order to distinguish it from NAFL. Del Chierico 
et al showed higher levels of 4-methyl-2-pentanone and 2-butanone in the serum of children with 
NASH.47 Higher levels of 2-butanone was seen in the serum of adults with NAFL52 but the 
functional significance of this metabolite is still unknown. In a cohort of 16 adults with biopsy 
proven NASH, patients with NASH had an increased ratio of primary to secondary bile acids, 
which the author correlated to an increased risk of hepatic injury.58 
NAFLD-related Advanced Fibrosis. In contrast to NAFL and NASH, which have data from both 
children and adults, NAFLD-related fibrosis has only been studied in adults due to the slow 
progression of fibrosis. Advanced fibrosis, defined as a fibrosis stage > 2, is associated with a 
higher incidence of mortality and liver cancer.59 Microbiome association studies of NAFLD-
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related advanced fibrosis usually reports a decrease in microbial diversity, often due to an increase 
in gram-negative bacteria.60–62 Multiple studies have found an association between advanced 
fibrosis and an overabundance of Bacteroides and Escherichia,60–63 while associations with other 
genera such as Prevotella have been less consistent.61,64  Utilizing metagenomic sequencing, which 
allows for species level resolution, Loomba et al showed that Escherichia coli and Bacteroides 
vulgatus were higher in patients with NAFLD-related advanced fibrosis.62 They also examined 
serum metabolites and showed that 3-phenylproanoate was the metabolite with the highest fold 
increase in advanced fibrosis, though it did not reach significance. Recently, Caussy et al found 
an association between 3-(4-hydroxyphenyl)lactate, a microbial metabolite involved in amino acid 
metabolism, to patients with NAFLD-related advanced fibrosis.63 This metabolite was also 
strongly correlated with several bacterial species that were also associated with hepatic fibrosis, 
including Escherichia coli, Bacteroides caccae and Clostridium sp.62 
POTENTIAL MECHANISMS THAT LINKS THE MICROBIOME TO FATTY LIVER 
DISEASE 
While recent human studies have provided meaningful insights into the composition and 
possible function of the microbiome in each stage in the development and progression of NAFLD, 
the findings are largely correlative and do not provide conclusive evidence of whether the 
microbiome is a critical driver of NALFD or simply responds to the altered diet and host 
environment associated with NAFLD. Mechanistic investigation supporting a causative role for 
the microbiome in NAFLD pathogenesis has largely depended upon animal models. The results of 
studies evaluating microbial composition and metabolites in animal models of NAFLD are 
summarized in Table 1-2.24,65–72 Overall, studies involving inflammatory pathways such as toll-
like receptor signaling, choline deficiency and bile acid metabolism have been linked to NASH 
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while pathways associated with short chain fatty acid and amino acid metabolism have been linked 
more to NAFL.  Here we will review the potential mechanisms by which the microbiome 
influences NAFLD development. 
Epithelial Barrier Function, Toll-Like Receptor Signaling and Endotoxemia. In adult patients with 
NAFLD as well as healthy patients on a Western diet, studies have shown that these patients were 
more likely to have a “leaky gut” characterized by higher intestinal permeability and altered tight 
junctions.73,74 This disruption in the epithelial gut barrier leads to an increased translocation of 
bacterial products, like lipopolysaccharide (LPS), into the portal circulation, potentially inducing 
hepatic inflammation. One of the very first studies to causally link the microbiome to NAFLD 
demonstrated that mice lacking inflammasome components – which are important to intestinal 
barrier defense – developed dysbiosis and NASH. Transfer of this dysbiosis to wild-type recipients 
could induce NASH via an influx of toll-like receptor (TLR) agonist, specifically TLR4 and TLR9, 
into the portal circulation.68  Rahman et al showed that fibrotic steatohepatitis induced by a high 
fat, high cholesterol and high fructose diet was exacerbated in mice lacking a gene involved in 
junctional adhesion molecules, an important component of the intestinal barrier. Administration 
of antibiotics improved liver histology in these knockout mice, suggesting that products of 
microbial metabolism crossing an impaired intestinal barrier mediated the phenotype.75 There is 
also a significant role of the host immune system in modulating gut permeability. Beta7 integrin-
deficient mice, which are deficient in intestinal immune populations requiring this integrin for 
chemotaxis, show decreased insulin resistance on a high fat diet.77 Treatment of wild-type 
C57BL/6 mice on a high fat diet with a local gut anti-inflammatory medication, 5-aminosalicyclic 
acid, reversed diet-induced bowel inflammation and improved metabolic parameters.77 The 
downstream effects of LPS translocation are mediated through induction of TLR signaling in the 
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liver. In several studies, LPS has been shown to induce TLR4, leading to increased NF-κB 
activation and cytokine production important to the progression from NAFL to NASH.78,79 
Unfortunately, a recent phase 2 trial did not show any significant benefit from TLR4 antagonism 
in NASH patients. Therefore, the clinical relevance of this pathway in remains unclear.80 
Choline Deficiency. The relationship between choline deficiency and NAFLD development has 
been well established.81 Deficiency in choline leads to abnormal phospholipid synthesis and 
alterations in VLDL secretion, eventually leading to hepatic steatohepatitis.81 Recently, dietary 
choline bioavailability was shown to be reduced by the gut microbiome through the production of 
metabolites such as trimethylamine (TMA).82 Several gut microbes are high utilizers of choline 
and only low abundance of these microbes is required to greatly reduce host choline levels.83 Mice 
fed a high fat diet have been shown to have increased levels of gut microbes that metabolize 
choline and produce TMA.84 TMA is converted to trimethylamine-N-oxide (TMAO) by liver 
flavin containing monooxygenase 3.85 Elevated levels of TMAO are associated with 
cardiovascular disease, which potentially links the extrahepatic manifestations of NAFLD to 
microbial derived metabolites.86 However, the role of circulating TMAO in NAFLD has not been 
well studied. 
Short-Chain Fatty Acids. One of the major functions of the human microbiome is the fermentation 
of indigestible carbohydrates (e.g. fiber) to produce short-chain fatty acids (SCFAs). These SCFAs 
include acetate, propionate, and butyrate, and they act as a major energy source for intestinal 
epithelial cells. SCFAs also facilitate a wide array of biological activities including hormone 
production and gene regulation.87 Obese individuals as well as individuals with NAFL have higher 
total levels of gut SCFAs as compared to lean controls.51,53,88 The administration of inulin-type 
fructan prebiotics was associated with a reduction in SCFAs in obese women along with a 
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reduction of other metabolic markers.89 Conversely, certain SCFAs may be beneficial against 
obesity and NAFLD. One mechanism by which SCFAs can affect the host is by binding to highly 
specific G-protein coupled receptors (GPR), which mediate distinct effects of each SCFA.  For 
example, in a mouse model of diet-induced obesity, a mixture of SCFA predominantly made up 
of butyrate reduced hepatic expression of GPR41 and GPR43, two receptors that have been shown 
to promote hepatic lipid accumulation.90,91 The positive effect of butyrate was further highlighted 
by Mattace Raso et al when they demonstrated that butyrate supplementation was able to improve 
hepatic steatosis induced in mice by a high fat diet.92 Furthermore, fecal microbial transplantation 
from lean human donors to obese patients resulted in improved insulin sensitivity, which was 
associated with increased abundance of butyrate-producing bacteria.93 The inconsistent findings 
on SCFAs is most likely due to the distinct biological effects of individual SCFAs on host 
metabolism.  
Bile Acid Metabolism. The recent development and marketing of obeticholic acid, a farnesoid X 
receptor (FXR) agonist, underscores the importance of bile acids for host metabolism and health. 
Gut microbes play a critical role in the regulation of the bile acid pool through conversion of 
primary bile acids to secondary bile acids, which have distinct functional properties mediated by 
differential binding to bile acid receptors including FXR and G-protein coupled bile acid receptor 
1 (GPBAR1).94 In a murine model of NAFLD, animals with intestine-specific FXR disruption 
developed changes in their gut microbiome that were associated with reduced triglyceride 
accumulation in response to a high fat diet as compared to controls.95 In mice treated with 
antibiotics, there was an increase in conjugated bile acid metabolites that inhibited intestinal FXR 
signaling.95 GPBAR1 signaling was also found to be necessary for sustained weight loss and 
improved fatty liver in mice undergoing sleeve gastrectomy.96 In humans, a phase 2 clinical trial 
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with obeticholic acid in patients with NASH showed improved NASH by histology after 72-weeks 
of treatment.97 The administration of obeticholic acid also led to a reversible induction of gram-
positive bacteria in the human small intestine and increased proportion of Firmicutes in mice.98  
While initial results are promising, ongoing studies and phase 3 trials are underway in order to 
better understand the complex relationship between the gut microbiome, bile acid synthesis, and 
FXR signaling. 
Amino Acid Metabolism. The gut microbiome can also affect the synthesis and metabolism of 
aromatic and branched-chain amino acids (BCAAs). In patients with insulin resistance, Prevotella 
copri and Bacteroides vulgatus were identified as the main species associated with increased 
BCAAs and insulin resistance.99 The authors also showed that mice gavaged with P. copri 
developed increased insulin resistance when fed a high fat diet as compared to controls.99 In a 
recent study, Hoyles et al. demonstrated that phenylacetic acid, an aromatic amino acid derived 
from microbial metabolism, was strongly associated with hepatic steatosis in humans.52 They also 
showed that the addition of phenylacetic acid in both primary human hepatocyte cultures and in 
mice models could trigger hepatic steatosis, implying a causal effect in NAFL.52 
THERAPEUTIC IMPLICATIONS, LIMITATIONS, AND FUTURE DIRECTIONS 
The growing evidence that links the human microbiome to NAFLD progression has 
motivated interest in the development of novel microbiome-related therapies for NAFLD. 
Microbiome-related interventions include gut-specific antibiotics, probiotics, prebiotics, and fecal 
microbial transplant (FMT).54 However, large well-designed clinical studies examining 
microbiome-related interventions in NAFLD are lacking. Several randomized controlled trials 
involving probiotics in NAFLD have yielded conflicting results due to the lack of standardization 
across studies.100 As of yet, no randomized controlled trial involving probiotics has shown any 
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significant changes in BMI.100 But several small trials have shown a potential benefit of probiotics 
on such important markers as insulin resistance, ALT, AST, and even histology grade (Table 1-
3).43,44,101–103  For example, a small randomized trial with 66 patients showed that supplementation 
with Bifidobacterium longum and fructo-oligosaccharides improved insulin resistance, hepatic 
steatosis and NASH activity index after 24 weeks of treatment.44  Whether these changes would 
hold up in larger trials is still unclear. There is also no data available yet about the role of FMT on 
NAFLD, but there are two actively recruiting clinical trials designed to address this question.104,105 
However, until there is a better understanding of the key mechanistic pathways by which the 
microbiome promotes NAFLD, the development of microbiome-related therapies will be limited. 
Nonetheless, a recent multi’omics study has provided initial support for the potential application 
of microbes and their metabolites as noninvasive biomarkers for diagnosis and prognostication of 
NAFLD.62 
Despite major recent advances in microbiome research, the field is still in its infancy with 
many areas that can be improved upon. One of the main issues that have made it challenging to 
interpret the existing literature on the microbiome and NAFLD is variation in study design. Some 
studies utilize healthy controls, while others select BMI-matched controls. There is also a wide 
age range, including separate studies of pediatric populations and adults. In addition, there is wide 
variation in how diet is incorporated into the analysis (if at all) and how samples are collected and 
processed. This makes comparisons across all NAFLD studies difficult to perform. Moreover, 
early studies examining the gut microbiome and NAFLD were predominantly association studies. 
These studies are unable to differentiate whether the microbial profile described was a potential 
cause of NAFLD or rather a byproduct of the environment. Furthermore, relevant microbial 
metabolites that reach the liver may be produced primarily in the small intestine and/or proximal 
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colon, which may not be well represented by the microbiome and metabolome of feces. At this 
time, studies are shifting away from these types of analysis and are moving towards studies 
focusing on mechanistic pathways by utilizing humanized animals and multi’omics analysis.106 By 
transplanting human microbiota into germ-free or antibiotic treated animals, researchers can 
establish causal relationship of dysbiosis with NAFLD development.  By using a multi’omics 
approach that combines microbiome analysis with other fields like proteomics and metabolomics, 
for example, researchers can better dissect mechanistic pathways that may lead to NAFLD 
development and progression. 
At this time, 16S rRNA sequencing is the most common method for microbiome 
analysis.106 It is effective for defining microbial composition and taxonomy to the genus and to 
some extent species level, but does not provide functional data (i.e. presence of bacterial genes 
and their expression level). In order to achieve this level of specificity, shotgun metagenomic 
sequencing is required. Unfortunately, due to its high cost, the sequencing of bacterial 
metagenomes and transcriptomes is still out of reach for many. But with ongoing advances in 
sequencing technology, it is likely that the cost of this service will be low enough for more 
widespread use in the future, similar to the widespread adoption of 16s rRNA sequencing after the 
dramatic decrease in sequencing costs early this decade.108 
CONCLUSIONS 
In summary, both animal models and human studies have supported the relationship between the 
gut microbiome and development and progression of NAFLD. By affecting gut barrier function, 
TLR signaling, choline metabolism, bile acid synthesis, SCFA and amino acid production, the gut 
microbiome appears to play a critical and multifactorial role in NAFLD development. But despite 
the advances in technology and bioinformatics analysis, specific mechanistic pathways are not yet 
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clearly defined. Future large, longitudinal, prospective studies incorporating multi-omics analysis 
and germ-free animals are needed to better define the multifactorial host-microbiome relationship 
involved in fatty liver pathogenesis. 
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NAFLD Subtypes Community Composition (Genera) Fecal Metabolites Serum Metabolites 
NAFL ↑↓pBifidobacterium46,52 
↑p↓Lactobacillus46,50,51,53 
↑↓pOscillobacter47,50,52,53 
↑p↓Prevotella48,49 
↑Roseburia53 
↑p↓Ruminococcus47,49,51 
↑Blautia47,49 
↑Clostridium50 
↑pDorea47,53 
↑Escherichia49,52 
↑Streptococcus50 
↓Alistipes50 
↓Coprococcus5152 
↓Faecalibacterium51 
↓Odoribacter50 
↓pOscillospira47 
↑Acetic Acid53 
↑Butanoic Acid53 
↑Cholic Acid58 
↑pEthanol48 
↑Isobutyric Acid51 
↑Propanoic acid53 
↑Propionate51 
↓2-butanone53 
↑p2-butanone47 
↑2-hydroxy-butyrate51 
↑Isoleucine52 
↑Leucine52 
↑L-lactic Acid51 
↑Phenylacetic Acid52 
↑Valine52 
NASH ↑p↓Ruminococcus46,51,57 
↑Allisonella56 
↑Blautia47,49 
↑Clostridium58 
↑Dorea46 
↑Escherichia48 
↑Lactobacillus46,57 
↑Parabacteroides56 
↓Bifidobacterium46,57 
↓Coprococcus51 
↓Faecalibacterium51,56,57 
↓Oscillospira46 
↑Chenodeoxycholic 
acid58 
↑Cholic Acid58 
↑Lithocholic Acid58 
↑p2-butanone47 
↑p4-methyl-2-
pentanone47 
↑Ethanol48 
NAFLD-Related 
Advanced Fibrosis 
↑↓Prevotella60,61 
↑↓Ruminococcus60–62 
↑Bacteroides60–63 
↑Blautia61 
↑Enterococcus61 
↑Escherichia62,63 
↑Klebsiella60 
↑Lactobacillus61 
↑Parabacteroides61 
↑Roseburia61 
↑Streptococcus61 
↓Akkermansia61 
 ↑3-(4-hydroxyphenyl)-
lactate63 
↑3-phenyl-
propanoate62 
Table 1-1: Bacteria genera and fecal/serum metabolites associated with different stages of non-
alcoholic fatty liver disease in human studies. p Denotes an association that has been reported only 
in pediatric cases of NAFLD. 
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NAFLD Animal 
Models 
Community Composition 
(Genera) Fecal Metabolites Serum Metabolites 
NAFL (high fat diet 
or leptin deficient 
mice) 
↑Bacteroides70 
↑Barnesiella72 
↑Bilophila7169 
↑Dorea71 
↑Helicobacter70 
↑Oscillospira70 
↑Roseburia72 
↑Sutterella71 
↓↑Allobaculum72 
↓↑Lactobacillus67,72 
↓Akkermansia69–71 
↓Bifidobacterium71 
↓Flavobacterium70 
↓Marinitoga70 
↓Parabacteroides70,71 
↓Ruminococcus71 
↑Butyrate24 
↓Deoxycholic acid 
(relative 
abundance)71 
↓Hyodeoxycholic 
acid (relative 
abundance)71 
Taurine conjugated 
bile acid71 
NASH (NASH 
inducing diet, i.e. 
methionine-choline 
deficient diet) 
↑(f) Bacteroidaceae68 
↑(f) Erysipelotrichaceae68 
↑(f) Porphyromonadaceae68 
↑(f) Clostridiaceae68 
↑Alistipes65 
↑Bacteroide65,66,68 
↑Bilophila66 
↑Blautia66 
↑Parabacteroides68 
↑Turicibacter68 
↓Akkermansia66 
↓Bifidobacteriu65,66 
↓Desulfovibrio66 
↓Enterorhabdus66 
↓Lactobacillus68 
↑Hexadecane65 
↑Tetracosane65 
↓Arachidic acid65 
↓Cholic acid65 
↓Stearic acid65 
 
Table 1-2: Bacterial genera and fecal/serum metabolites associated with NAFL and NASH 
development in animal models. Wild-type mice on a control diet serve as the reference group. 
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Study Number of 
Patients 
Intervention Major Findings 
Aller et al.101 30 Lactobacillus bulgaricus + 
Streptococcus thermophilus vs 
placebo for 3 months 
Decrease in ALT, 
AST, GGT 
Alisi et al.102 44p VSL#3 vs placebo for 4 months Ultrasound 
improvement in 
fatty liver 
Eslamparast et al.103 19 Synbiotic vs placebo for 28 weeks Decrease in ALT, 
AST, GGT, CRP, 
TNFα, fibrosis 
score by transient 
elastography 
Malaguarnera et al.44 66 Bifidobacterium longum + fructo-
oligosaccharides + life-style 
modification vs life-style 
modification alone 
Decrease in AST, 
LDL, CRP, TNFα, 
HOMA-IR, 
steatosis, and 
NASH activity 
index 
Shavakhi et al.43 64 Protexin + Metformin vs 
Metformin alone 
Decrease in ALT, 
AST, ultrasound 
grading of steatosis 
Wong et al.109 20 Lepicol vs nothing Decrease in 
intrahepatic 
triglyceride content 
as measured by 
proton-magnetic 
resonance 
spectroscopy 
Table 1-3: Summary of randomized control trials involving NAFLD and probiotics. p Denotes a 
pediatric trial. 
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INTRODUCTION 
Obesity has reached global epidemic proportions and has become the leading preventable 
cause of death, both in the United States and worldwide. Current estimated global prevalence rates 
are as high as 500 million adults who are considered obese, and these numbers continue to rise 
dramatically.1 Obesity is associated with many comorbidities including numerous cancers and 
musculoskeletal disorders, diabetes, and premature mortality from cardiovascular disease (CVD).2 
In addition to health detriments, economic and social consequences of obesity are compounding. 
In 2011, medical costs associated with treatment of preventable diseases associated with obesity 
were estimated to increase by $48-66 billion/year in the U.S. alone, with an estimated 65 million 
more adults to become obese by 2030.3 
Food addiction (FA) is a potential driver of obesity where the hedonic aspect of ingestive 
behaviors overrides the homeostatic mechanisms.4 Overeating and sedentary lifestyles result in a 
positive energy imbalance, leading to adipose tissue accumulation. According to the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV), criteria for the diagnosis of substance 
addiction includes: 1) taking the substance in larger amounts than was intended, 2) inability to 
control its use, 3) taking the substance for a longer period of time than was intended, and 4) 
continued use despite adverse consequences.5 For those that study FA, the Yale Food Addiction 
Scale (YFAS) has been developed and validated as a psychometrically sound measure to 
operationalize human cases of FA using the DSM-IV criteria for substance abuse.4 While many 
believe that FA is a distinct entity from other behavioral eating disorders, the concept of food 
addiction is still a controversial issue even within the newest update of the DSM-V.6 
Both obesity and FA can affect the connectivity of the brain. In several human cross-
sectional studies, obesity has been shown to be significantly associated to alterations of the brain’s 
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dopaminergic pathways in the brain’s reward system (i.e. striatum, prefrontal cortical regions and 
amygdala).7 These alterations are associated with dysregulation of reward sensitivity, motivation, 
and impulse control associated with unregulated ingestive behaviors.7 FA has been shown to be 
correlated with neural activation in key reward brain regions which are activated in other addiction 
disorders and contributes to increased cravings, reduced inhibitory control related to ingestive 
behaviors, and higher levels of obesity.8 Recent evidence has shown that obesity with hedonic or 
disinhibited eating patterns is associated with increased dopaminergic and GABA signaling both 
in animal and human models of food addiction and obesity.6 
The gut microbiome is also another area that is gaining recognition as a significant player 
in the etiology of many diseases as well as obesity. Research has shown that deviation from a core, 
lean gut microbiome profile is reflective of obesity.9 In addition to reduced bacterial diversity, 
there is alteration in bacterial gene representation and phylum-level modifications.9 Obesity-
associated gut microbiomes also show altered pathways of food metabolism. Correlations between 
obesity pathophysiology and the gut microbiome have been observed through metagenomic and 
biochemical analyses, demonstrating that obese gut microbiomes absorb energy at higher 
efficiencies than lean gut microbiomes.10 This superfluous harvesting of energy results in 
accumulation of body fat. Existing studies have focused on the effect of short chain fatty acids 
(SCFAs) on ingestive behavior in animal models.11 However, given our current understanding of 
the gut microbiome and obesity, there are very few studies that have examined the relationship 
between the gut microbiome and its metabolites with ingestive behaviors in obesity, especially in 
humans. Among these very few studies, tryptophan metabolites have been most closely implicated 
in modulating brain-gut-microbiome interactions within this context.12 
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Given these relationships, we aimed to test the hypothesis that the role of microbial profiles 
and tryptophan metabolites were significantly associated with food addiction as well as key reward 
regions of the brain in females with high BMI. 
 
METHODS 
Subject population 
The prevalence of FA differs by sex, with females with obesity having a higher prevalence 
(15-30%) than males with obesity (~5%).6  Due to the higher prevalence of FA in females,6 we 
focused our analysis to female subjects. The sample was comprised of 105 right-handed female 
subjects, between the age of 18-50 years old without significant medical or psychiatric conditions. 
Medical and psychiatric conditions were screened using a standardized screening sheet and a 
physical exam by a trained registered nurse. Subjects were excluded for the following reasons: 
pregnant or lactating, substance use disorder, abdominal surgery, tobacco dependence (half a pack 
or more daily), extreme strenuous exercise (>8h of continuous exercise per week), current or past 
psychiatric illness and major medical (including inflammatory bowel disease, active malignancy, 
organ failure, and diabetes) or neurological conditions (including Alzheimer’s disease, Parkinson’s 
disease, history of stroke, traumatic brain injury, or seizure disorder). Subjects taking medications 
that interfere with the central nervous system or regular use of analgesic drugs were excluded. 
Since female sex hormones such as estrogen are known to effect brain structure and function, we 
only included females who were premenopausal. Subjects with hypertension, diabetes, metabolic 
syndrome or eating disorders were excluded to minimize confounding effects. No subjects 
exceeded 400lbs due to magnetic resonance imaging scanning weight limits. Subjects were also 
excluded if they had been on antibiotics or probiotics with 3 months of recruitment. 
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Multimodal magnetic resonance brain imaging (MRI), anthropometrics (height, body 
weight, and waist-hip ratio measurements, body mass index), measures of appetite and FA, and 
stool samples for 16S ribosomal RNA gene sequencing and metabolomics were collected. 
All procedures complied with the principles of the Declaration of Helsinki and were 
approved by the Institutional Review Board at our institution (IRB # 16-000187). 
Food Addiction Questionnaire 
FA was assessed using the Yale Food Addiction Scale (YFAS) questionnaire, a 25-item 
scale developed to assess food addiction by assessing signs of substance-dependence symptoms in 
eating behavior.13 This scale is based upon the substance dependence criteria as found in the DSM-
4 (e.g., tolerance [marked increase in amount; marked decrease in effect], withdrawal [agitation, 
anxiety, physical symptoms], and loss of control [eating to the point of feeling physical ill]).13 The 
YFAS questionnaire is a 25-question survey that measures several aspects of FA behavior: food 
dependence, withdrawal, tolerance, continued use despite problems, time spent eating, loss of 
control, inability to cut down, and clinically significant impairment. Food addiction was defined 
as having a YFAS symptom count >3 with clinically significant impairment or distress. Clinically 
significant impairment or distress was defined as having a at least one positive response to the 
following two questions in the YFAS questionnaire: “My behavior with respect to food and eating 
causes significant distress” and “I experience significant problems in my ability to function 
effectively (daily routine, job/school, social activities, family activities, health difficulties) because 
of food and eating,” similar to previously published works.6 The YFAS has displayed a good 
internal reliability (Kuder–Richardson α=0.86).13 
Intestinal Microbial 16S rRNA Gene Sequencing 
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Stool was collected within 1 week of the patient’s brain MRI scan. All samples were stored 
at -80oC before 16S rRNA sequencing. DNA was extracted from frozen fecal samples using the 
PowerSoil DNA Isolation Kit (MO BIO Laboratories, Carlsbad, CA) with bead beating following 
the manufacturers protocol. The V4 hypervariable region of the 16S rRNA gene was amplified 
using the 515F and 806R primers. PCR products were purified by a commercial kit and sequenced 
on the Illumina HiSeq 2500 platform. The base pair reads were processed using QIIME v1.9.1 
with default parameters. The taxonomic assignments of sequences were performed using closed 
reference operational taxonomic unit (OTU) picking in QIIME against the Greengenes database 
pre-clustered at 97% identity. OTUs were removed if they were present in less than 10% of 
samples. 
Fecal metabolomics 
Fecal samples were aliquoted under liquid nitrogen and shipped to Metabolon for 
processing and analysis as a single batch on their global metabolomics and bioinformatics 
platform. Data was curated by mass spectroscopy using established protocols and software as 
previously described. Because of our interest in the gut-brain axis in obesity, only tryptophan 
derived metabolites were examined. 
Brain Magnetic Resonance Imaging 
Whole brain structural and anatomical connectivity (diffusion tensor imaging; DTI) data 
was acquired using a 3.0T Siemens Prisma MRI scanner (Siemens, Erlangen, Germany). DTI 
measures the microscopic properties of white- matter and fiber track connectivity. Detailed 
information on the standardized acquisition protocols, quality control measures, and image 
preprocessing are provided in previously published studies.14 
Acquisition: 
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Structural MRI. High resolution T1-weighted images were acquired: echo time/ repetition 
time (TE/TR) =3.26ms/2200ms, field of view (FOV)=220×220mm slice thickness=1mm, 176 
slices, 256×256 voxel matrices, and voxel size=0.86×0.86×1mm. 
Diffusion-weighted MRI. Diffusion-weighted magnetic resonance imaging was acquired 
according to two comparable acquisition protocols, in either 61 or 64 noncolinear directions with 
b=1000 s mm−2, with 8 or 1 b=0 s mm−2 images respectively, TE/TR= =88ms/ TR=9500 ms, and 
FOV =256 mm with an acquisition matrix of 128x128, and a slice thickness of 2 mm, resulting in 
DTI data with 2mm isotropic resolution. 
Quality Control and Preprocessing of images: 
Structural images were included based on compliance with acquisition protocol, full brain 
coverage, minimal motion (Gibbs ringing), absence of flow/zipper, and minor atrophy/vascular 
degeneration. Preprocessing for quality control involved bias field correction, co-registration, 
motion correction, spatial normalization, tissue segmentation, Fourier transformation for 
frequency distribution, and specific quantitative checks for DTI images (apparent diffusion 
coefficient and fractional anisotropy [FA]) as previously described.15 Preprocessing for diffusion-
weighted imaging included visually checking for artifacts and motion on the raw diffusion 
weighted and b0 images, visual assessment of FA and mean diffusivity (MD) map quality, as well 
checking for physiologically feasible FA and MD values (FA of 0–0.1 and MD of 3–4 μm2/ms in 
ventricles, and FA of 0.6–0.9 and MD of 0.6–0.9 μm2/ms in splenium of corpus callosum). 
Maximum relative motion thresholds for translation and rotation for each direction (x, y, and z) 
were set at 2mm and 2°, respectively. No subjects presented with serious adverse imaging artifacts 
and no subjects exceeded motion thresholds. 
Structural Image Parcellation and Anatomical Pairwise Network Construction: 
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T1-image segmentation and regional parcellation were conducted using FreeSurfer 
v.5.3.016,17 following the nomenclature described in the Destrieux and Harvard-Oxford subcortical 
atlas.18 This parcellation results in the labeling of 165 regions, 74 bilateral cortical structures, 7 
subcortical structures, the midbrain, and the cerebellum.19 
Regional parcellation and tractography results were combined to produce a weighted, 
undirected connectivity matrix. The final estimate of white matter connectivity between each of 
the brain regions was determined based on the number of fiber tracts intersecting each region. 
Weights of the connections were then expressed as the absolute fiber count divided by the 
individual volumes of the two interconnected regions.20 
Brain Regions of Interest 
Based on previous research,14 regions of interest were restricted to core regions of the 
reward network (basal ganglia: caudate nucleus, globus pallidum, putamen, thalamus, nucleus 
accumbens (NAcc), amygdala, and brainstem [including the substantia nigra/SN and ventral 
tegmental area/VTA]), as these regions have been implicated in brain-gut axis alterations 
associated with obesity.21 
Statistical Analysis 
Baseline demographic characteristics differences were compared using student’s test for 
continuous variables and chi-squared test for categorical variables. Means are expressed with their 
respective standard deviation. Multilevel sparse partial least square linear discriminant analysis 
(sPLS-DA) was done to analyze microbiome data using the Mixomics package in R 
(http://www.R-project.org). sPLS-DA identifies OTUs that discriminated subjects with no FA 
from those with FA by simultaneously performing feature selection and modeling using lasso 
penalization. sPLS-DA operates using a supervised framework to find linear combinations of a 
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limited set of variables, here OTUs, that predicts FA status, similar to prior published works.22 
Microbial alpha diversity (i.e. diversity within a sample) were calculated in QIIME using OTU-
level data rarefied to 34,222 sequences. The significance of differences in alpha diversity metrics 
- Faith’s phylogenetic diversity (Faith’s PD), Chao1, and Shannon index - was calculated by 
analysis of variance. Association of microbial genera with or without FA were evaluated using 
DESeq2 in R, which employs an empirical Bayesian approach to shrink dispersion and fit non-
rarified count data to a negative binomial model. P-values for differential abundance were 
converted to q-values to correct for multiple hypothesis testing (< 0.05 for significance). 
Metabolomics data were normalized and then fitted to a gaussian model with the limma package 
in R. Brain imaging data was compared between individuals without FA as compared to those with 
FA using a generalized linear model in R and p-values adjusted using false discover rate for 
multiple comparisons. Because obesity is closely related to FA, microbial analysis, metabolomics, 
and brain imaging analysis was all adjusted for obesity by doing subgroup analysis of obese 
patients with or without FA, and normal weight individual versus patients with obesity without 
FA. A BMI of <25 was considered normal, a BMI > 30 as obese. To determine microbial 
associations with brain imaging data and metabolomics, significant variables were dichotomized 
based on their median values before being applied to DESEq2 in R. 
Random Forest Classifier 
A random forest classifier was created in R to identify obese subjects with FA using the 
randomForest package (https://cran.r-project.org/web/packages/randomForest) with 1001 trees 
and mtry=2. The number of trees were varied from 100 to 10,000 at intervals of 500, and 1000 
trees were selected as the parameter as it minimized the out-of-bag estimate of error. An odd 
number was used to prevent theoretical ties that may occur from forest generation. Similarly, 
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various mtry were selected and an mtry of 2 was used as it gave the highest area under the receiver 
operating curve (AUC). Features in the random forest classifier included OTUs that were 
significantly different by DESeq2 analysis and metabolites and brain imaging data that was 
statistically different in obese subjects with FA. The accuracy of the random forest classifier was 
estimated using a 5-fold cross-validation. 
 
RESULTS 
Patient Characteristics 
105 female subjects were enrolled in the study. The average age was 32.4 years + 10.2. 
Based on a YFAS symptom count of >3 with clinically significant impairment or distress, 
indicating the presence of FA, 19 subjects (18.1%) were identified with FA (Table 2-1). There 
was no statistical difference by age in subjects with FA as compared to those without FA. 89.5% 
(17/19) of the subjects with FA were obese as compared to 39.5% (34/86) of subjects without FA. 
The average BMI in subjects with FA was 35.6 + 5.3 and the average BMI in subjects without FA 
was 29.1 + 5.4 (p-value=0.0001). There were no statistical differences between subjects with FA 
or without FA in regards to race or ethnicity (p-value =0.55). 
Gut microbial signature as it relates to food addiction 
There were no statistical differences in beta-diversity using Bray-Curtis dissimilarity 
between obese subjects with or without FA. There were also no statistical differences in any alpha 
diversity metrics between the microbial samples of obese subjects with FA as compared to those 
without FA. However, there was a significant difference in alpha diversity metrics by 
race/ethnicity with Caucasians and African-Americans having higher diversity than Hispanics. 
After adjusting for race/ethnicity there were no differences in subjects with a BMI of >25 to normal 
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weight individuals by any alpha diversity metric. The taxonomic profiles of subjects with FA 
compared to subjects without FA on a phylum and genus level are summarized in Figure 3-1a 
and 3-1b, respectively. DESEq2 analysis of patients without FA identified 22 distinct OTUs that 
were associated with obesity as compared to normal weight individuals (Figure 3-1c). Six OTUs 
were negatively correlated and 16 OTUs were positively correlated to obesity. The four highest 
abundant OTUs belong to the genera Bacteroides, and Prevotella. The OTU with the greatest 
negative fold change was Akkermansia muciniphila. DESEq2 analysis of patients with obesity 
identified 15 OTUs that were associated with FA (Figure 3-1d). Ten OTUs were negatively 
associated with FA and 5 OTUs were positively associated with FA. The largest abundant OTU 
belonged to the genus Bacteroides, while the OTU with the largest positive fold change was 
Megamonas and the OTU with the largest negative fold change was Eubacterium biforme. 
Similarly to patients with obesity without FA as compared to normal weight patients, Akkermansia 
muciniphila was negatively associated with FA in patients with obesity. 
Supervised learning methods were applied to identify a distinct microbial signature that 
differentiated between obese subjects and normal weight subjects without FA (Figure 3-2a and 
3-2b) as well as obese subjects with or without FA (Figure 3-2c and 3-2d). Through the model, 
patients with normal BMIs were separated from patients with obesity by differences in OTUs 
belonging to such taxa as Bacteroides, Blautia, Lachnospiraceae, Ruminococcaceae, Roseburia, 
Faecalibacterium and Clostridium.  In patients with obesity, over 30 different OTUs separated 
patients with FA from those without FA. Notable OTUs that distinguished patients without FA 
included Eubacterium biforme and Bacteroides. Streptococcus was the taxa with the largest 
contribution for obese subjects with FA. 
Brain reward networks and food addiction 
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DTI pairwise MRI showed greater anatomical connectivity between the putamen (a key 
reward region) and the brain stem (Cohen’s d =1.12, p.adj value= 0.0415) and intraparietal 
sulcus/transverse parietal sulcus (IntPS/TrPS) (Cohen’s d=0.89, p.adj value=0.002) in obese 
subjects with FA compared to those subjects without FA (Figure 3-3a, 3-3b, 3-3c). Using DESEq2 
analysis and dichotomizing the brain imaging data based on their respective median values, 17 
OTUs were associated with an increase communication between the brain stem and the putamen 
(Figure 3-3e). Similarly, 10 OTUs were associated with an increase communication between the 
putamen and the IntPS/TrPS (Figure 3-3f). The OTU belonging to the genus Megamonas was 
positively associated with increase connectivity in both of these brain regions. Conversely, OTUs 
that belonged to Bacteroides and Eubacterium were negatively associated with the connections of 
both of these brain regions. Akkermansia was also negatively associated with the connection 
between the putamen and the IntPS/TrPS but was not associated with the connection between the 
putamen and the brain stem. There were no significant differences in DTI pairwise MRI brain 
imaging of patients with obesity without FA as compared to normal weight individuals. There 
were also no significant differences when comparing obese and overweight patients without FA to 
normal weight individuals. 
Indolepropionate is associated with food addiction 
By analyzing fecal metabolites that were related to tryptophan metabolism, we found that 
indolepropionate was negatively associated with FA in patients with obesity (Cohen’s d, 0.74, p-
value=0.045) (Figure 3-3d). By analyzing the level of indolepropionate with fecal microbiome 
data, we discovered 14 OTUs that were correlated with indolepropionate (Figure 3-3g). The 
highest abundant OTU that positively correlated to indolepropionate belonged to the genus 
Bacteroides. The highest abundant OTU that was negatively correlated to indolepropionate 
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belonged to the genus Prevotella. All the OTUs that were positively associated with 
indolepropionate belonged to Akkermansia muciniphila and Bacteroides. There were no 
significant differences in fecal tryptophan metabolites of patients with obesity without FA as 
compared to normal weight individuals. There were also no significant differences in fecal 
metabolites when comparing obese and overweight patients without FA to normal weight 
individuals. 
 
Random forest classifier based on brain imaging, fecal metabolite, and 16S sequencing 
accurately identifies subjects with food addiction 
Using the significant findings on brain imaging, fecal metabolite, and DESEq2 analysis of 
the fecal microbiome, a random forest classifier was created with a high accuracy for predicting 
obese subjects with FA behaviors. The AUC in 5-fold cross-validation was 0.81 (Figure 3-4a). 
The contribution of each variable was expressed with a variable importance score, which measures 
the decrease in accuracy of the classifier if that feature was removed. The variables with the highest 
scores were those pertaining to brain imaging and indolepropionate. Seven OTUs also contributed 
significantly to the classifier and those OTUs belonged to Barnesiellaceae, Ruminococcaceae, 
Desulfovibrio, Bacteroides, Eubacterium, and Megamonas (Figure 3-4b). 
 
DISCUSSION 
To our knowledge, this is the first study to utilize a systems biology approach to 
demonstrate associations between FA and changes in brain-gut-microbiome interactions by 
analyzing fecal microbes, metabolites, and anatomical connectivity (DTI) brain data. FA behaviors 
in females were associated with a distinct microbial profile, increased connectivity with the 
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putamen of the reward center of the brain, and a decrease in indolepropionate, a tryptophan derived 
microbial metabolite. 
The study results indicated a strong negative association between Bacteroides, Akkermansia, and 
Eubacterium with FA. Bacteroides is the major genus belonging to the phylum Bacteroidetes. In 
both human and mouse studies, a rise in Bacteroidetes is often associated with a leaner 
phenotype.10 In bariatric studies, subjects that had the most significant weight loss were those that 
had higher levels of Bacteroides and lower levels of Prevotella.23 In a prospective study, 
Bacteroides species were higher in lean individuals and those subjects who were able to achieve 
weight loss as compared to subjects with obesity.24 Whether the associations noted between 
Bacteroides and obesity are causative is still an area of active research. In our data, Bacteroides 
was positively associated with indolepropionate and negatively associated with brain regions 
related to FA. 
Akkermansia was also another genus that was significantly associated with FA, brain 
imaging, and fecal metabolites. Akkermansia is a mucin-degrading bacterium that has been 
extensively studied for its protective role in metabolic syndrome and insulin sensitivity both in 
human and mouse studies.25 In a study of 41 females with obesity undergoing calorie restriction, 
an increase in relative abundance of Akkermansia was associated with improved fasting glucose, 
waist-to-hip ratio, and subcutaneous adipocyte diameter.26 This led to a recent phase 1 randomized 
double-blind, placebo- controlled clinical trial showing that Akkermansia supplementation in 
obese/overweight volunteers led to improved insulin sensitivity, reduced plasma cholesterol, and 
a trend towards decreased body weight and fat mass.27 
However, unlike Akkermansia and Bacteroides, Eubacterium biforme has not been as well 
studied with regards to obesity or metabolic syndrome. In our study we show Eubacterium to be 
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negatively associated with FA as well as key areas of the brain reward network. Similar to 
Bacteroides, Eubacterium is known to be a significant producer of short-chain fatty acids.28 Short-
chain fatty acids is the by-product of bacterial fermentation of indigestible dietary fiber. The most 
abundant short-chain fatty acid is butyrate and several animal studies have shown that butyrate can 
be protective against obesity by increasing GLP-1, leptin release, and increasing fatty acid 
oxidation.28 Butyrate is also able to communicate directly with the central nervous system by 
crossing the blood-brain barrier and activating the vagus nerve and hypothalamus. 28 
While Akkermansia, Bacteroides, and Eubacterium were negatively associated with FA, 
Megamonas was one of the few bacteria that was both positively associated with FA and an 
increased activity of the reward network of the brain. In human studies, Megamonas has been 
associated with an increase prevalence of prediabetes 29 and childhood obesity.30  In context, these 
associations between the gut microbiome and obesity may be mediated through interactions 
involving the gut-brain axis. 
In our study, we also saw that alpha diversity did not differ between subjects with or 
without FA but it was seen that alpha diversity did differ by race and ethnicity, which may be a 
reflection of dietary differences across these groups. Larger samples will allow for future analyses 
to account for cultural factors and for race and ethnicity differences. 
Analysis of fecal metabolites revealed a negative association between indolepropionate and FA. 
Microbial analysis showed that Bacteroides and Akkermansia was positively correlated with 
indolepropionate while bacteria belonging to the phylum Firmicutes were negatively associated. 
This finding is in line with the numerous studies that have shown an increase in Firmicutes and a 
decrease in Bacteroides in patients with diabetes, metabolic syndrome and obesity.31 
Indolepropionate belongs to a larger class of tryptophan-derived metabolites termed “indoles.” In 
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contrast to other tryptophan derived metabolites (serotonin, kynurenine), which have also been 
implicated in brain-gut-microbiome interactions in obesity, indoles are the result of exclusively 
microbial metabolism, in which most undigested dietary tryptophan in the gut is converted to 
indoles.32 The results we present here are consistent with our previously published work, where 
we describe associations between indoles on key regions of the extended reward network and both 
obesity and FA.12 Indoles play an important role in modulating kynurenine synthesis, reducing 
central nervous system inflammation, improving the mucosal intestinal barrier, and altering GLP-
1 secretion33,34 all of which have been shown to be disrupted in states of obesity. Although 
indolepropionate has been less extensively studied, previous work has demonstrated a 
neuroprotective role of indolepropionate against Alzheimer’s disease and neural oxidative stress.35 
Furthermore, a Finnish study of 200 subjects showed that a higher level of serum indolepropionate 
acid was associated with a reduce risk of type 2 diabetes.36 This data suggests that indolepropionate 
may have both local protective effects on intestinal barrier function as well as remote effects on 
preserving β-cell function and central nervous system inflammation. 
In this study we were also able to demonstrate that decreased fecal indolepropionate was 
associated with not only increased FA behaviors, but that this was related to increased connectivity 
between key reward regions involving the putamen. In line with the previous fecal microbiome 
data in FA and indolepropionate, we see a negative association of Bacteroides and Akkermansia 
to the connectivity between the putamen and the intraparietal sulcus. Normal eating behavior is 
under the control of the brain’s homeostatic system and hedonic system, which includes regions 
involved in the processing of food-seeking behavior, inhibition, and integrating information to 
make decisions regarding food intake.37,38 However, in both FA and obesity, activity within the 
extended reward network can override the homeostatic system.8,37 This dominance of hedonic over 
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homeostatic influences on eating behavior has been related to the ubiquitous presence of cheap, 
highly palatable, high caloric foods, which are enhanced for taste and salience. This hedonic 
dominance not only leads to increases in cravings and ingestion of these foods, but environmental 
factors such as stress and adversity can serve as conditional cues for future food intake and long-
term weight gain.39 Some studies have indicated that overconsumption of highly palatable foods 
rich in calories, fat, and sugar reduce the reward thresholds of such foods when ingested, and 
therefore require a higher intake to generate the same satisfaction.40 
Integrating the significant findings on brain imaging, fecal metabolites, and the fecal 
microbiome, we created a random forest classifier, which demonstrated a high accuracy for 
predicting obese individuals with FA behaviors. Next to indolepropionate and connectivity of key 
reward network region (the putamen), the bacterial genera with significant contribution to the 
classifier that were also significant in other analysis belonged to Bacteroides, Eubacterium, and 
Megamonas. 
There are several limitations to our study. Because of the cross-sectional design the results 
only show associations between behavior, gut microbiome and brain structure. However, in the 
absence of a truly valid food addiction model in animals and the challenges of doing studies in 
humans that address the bidirectional BGM interactions, cross sectional studies are essential first 
steps to identify correlations within the BGM axis in humans. Another limitation is that this study 
enrolled only females, and due to the lower prevalence rates of FA in males compared to females, 
it would require larger sample sizes to observe the same effects in males. Lastly, this data should 
be validated in an external cohort to confirm the accuracy of the classifier. 
In conclusion, food addiction refers to maladaptive ingestive behaviors resulting from a 
shift from primarily homeostatic to hedonic regulatory mechanisms of food intake which 
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primarily occurs in individuals with obesity. This shift reflects alterations at all levels of the BGM 
axis. The results of our study suggest that FA behavior may be mediated via effects of the gut 
microbiome and their metabolites on the reward centers of the brain (Figure 3-5). If confirmed in 
follow up studies, these findings suggest the possibility of targeting the brain-gut-microbiome axis 
to combat FA behavior and obesity. 
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Table 2-1: Baseline characteristics by food addiction 
  
No Food Addiction 
(No FA) (n=86) 
Food Addiction (FA) 
(n=19) p-value 
Age (mean +/- SD) (yrs) 33.19 + 10.31 28.57 + 8.66 0.07 
BMI (mean +/- SD) 29.1 + 5.4 35.6+ 5.3 0.0001 
Normal Weight (n=16) 
% 18.60 0.00 
0.0001 
Overweight (n=38) % 41.86 10.52 
Obese (n=51) % 39.53 89.47 
YFAS Symptom Count 
(mean +/- SD) 1.15 + 0.77 3.63 + 1.16 <0.0001 
Race/Ethnicity 
Hispanic (n=41) % 36.05 52.63 
0.55 
Caucasian (n=28) % 23.26 42.11 
African American 
(n=13) % 12.79 10.53 
Asian (n=21) % 20.93 15.79 
Other (n=2) % 2.33 0 
SD: Standard deviation 
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Figure 2-1: Several taxa are associated with food addiction. Taxonomic profiles between subjects 
with No Food Addiction (No FA) and Food Addiction (FA) on a (a) phylum and (b) genus level. 
Only taxa > 1% relative abundance are shown. (c) DESEq2 analysis of patients without FA 
comparing those with obesity and those with normal BMI showing several OTUs associated with 
Obesity. (d) DESEq2 analysis of only patients with obesity showing several OTUs that are 
associated with FA. 
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Figure 2-2: A distinct microbial profile differentiates subjects with obesity and food addiction 
from those without. A) Plot of the partial least square discriminant analysis of the gut microbiome 
composition between subjects with obesity without food addiction versus those with normal BMI 
and without FA along with their 95% confidence ellipses and B) contributing OTUs to component 
1. C) Plot of the partial least square discriminant analysis of the gut microbiome composition 
between obese subjects with food addiction versus those without FA along with their 95% 
confidence ellipses and D) contributing OTUs to component 1. 
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Figure 2-3: Brain imaging and indolepropionate is associated with food addiction. DTI pairwise 
showed that the communication between the intraparietal sulcus/transverse parietal (IntPS/TrPS) 
sulcus and brain stem to the putamen was positively associated with Food Addiction (FA) in 
patients with obesity. A) Schematic diagram of the significant brain region associated with food 
addiction and its quantification (B and C). D) Levels of fecal indolepropionate in obese subjects 
with or without food addiction (FA). E) DESEq2 analysis in obese subjects showing several OTUs 
associated with increase connectivity between the brain stem and the putamen. F) DESEq2 
analysis in obese subjects showing several OTUs associated with increase connectivity between 
the IntPS/TrPS to the putamen.  G) The OTUs that are correlated to fecal indolepropionate by 
DESEq2 in patients with obesity. IntPS/TrPS: intraparietal sulcus/transverse parietal sulcus. Pu: 
Putamen. 
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Figure 2-4: Combining fecal metabolite with 16S and brain imaging data, a highly accurate 
classifier is created that identifies subjects with food addiction (FA). A) ROC curve for the random 
forest classifier (AUCROC =0.81). B) Variable importance plot of each factor on the accuracy of 
the classifier. IntPS/TrPS: intraparietal sulcus/transverse parietal sulcus. Pu: Putamen. 
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Figure 2-5: Proposed schematic diagram that connects the gut microbiome to food addiction (FA) 
via changes in metabolite and changes in connectivity of the brain’s reward system. 
  
 54 
REFERENCES 
1 Seidell, J. C. & Halberstadt, J. The global burden of obesity and the challenges of 
prevention. Ann Nutr Metab 66 Suppl 2, 7-12, doi:10.1159/000375143 (2015). 
2 Reilly, J. J. & Kelly, J. Long-term impact of overweight and obesity in childhood and 
adolescence on morbidity and premature mortality in adulthood: systematic review. Int J 
Obes (Lond) 35, 891-898, doi:10.1038/ijo.2010.222 (2011). 
3 Wang, Y. C., McPherson, K., Marsh, T., Gortmaker, S. L. & Brown, M. Health and 
economic burden of the projected obesity trends in the USA and the UK. Lancet 378, 815-
825, doi:10.1016/S0140-6736(11)60814-3 (2011). 
4 Gearhardt, A. N., Corbin, W. R. & Brownell, K. D. Development of the Yale Food 
Addiction Scale Version 2.0. Psychol Addict Behav 30, 113-121, doi:10.1037/adb0000136 
(2016). 
5 Corwin, R. L. & Grigson, P. S. Symposium overview--Food addiction: fact or fiction? J 
Nutr 139, 617-619, doi:10.3945/jn.108.097691 (2009). 
6 Gordon, E. L., Ariel-Donges, A. H., Bauman, V. & Merlo, L. J. What Is the Evidence for 
"Food Addiction?" A Systematic Review. Nutrients 10, doi:10.3390/nu10040477 (2018). 
7 Fletcher, P. C. & Kenny, P. J. Food addiction: a valid concept? Neuropsychopharmacology 
43, 2506-2513, doi:10.1038/s41386-018-0203-9 (2018). 
8 Lindgren, E. et al. Food addiction: A common neurobiological mechanism with drug 
abuse. Front Biosci (Landmark Ed) 23, 811-836, doi:10.2741/4618 (2018). 
9 Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480-
484, doi:10.1038/nature07540 (2009). 
10 Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for 
energy harvest. Nature 444, 1027-1031, doi:10.1038/nature05414 (2006). 
11 Goswami, C., Iwasaki, Y. & Yada, T. Short-chain fatty acids suppress food intake by 
activating vagal afferent neurons. J Nutr Biochem 57, 130-135, 
doi:10.1016/j.jnutbio.2018.03.009 (2018). 
12 Osadchiy, V. et al. Correlation of tryptophan metabolites with connectivity of extended 
central reward network in healthy subjects. PLoS One 13, e0201772, 
doi:10.1371/journal.pone.0201772 (2018). 
13 Gearhardt, A. N., Corbin, W. R. & Brownell, K. D. Preliminary validation of the Yale Food 
Addiction Scale. Appetite 52, 430-436, doi:10.1016/j.appet.2008.12.003 (2009). 
14 Gupta, A. et al. Early adverse life events are associated with altered brain network 
architecture in a sex- dependent manner. Neurobiol Stress 7, 16-26, 
doi:10.1016/j.ynstr.2017.02.003 (2017). 
15 Gupta, A. et al. Sex commonalities and differences in obesity-related alterations in intrinsic 
brain activity and connectivity. Obesity (In press). 
 55 
16 Fischl, B. et al. Whole brain segmentation: automated labeling of neuroanatomical 
structures in the human brain. Neuron 33, 341-355 (2002). 
17 Dale, A. M., Fischl, B. & Sereno, M. I. Cortical surface-based analysis - I. Segmentation 
and surface reconstruction. NeuroImage 9, 179-194 (1999). 
18 Destrieux, C., Fischl, B., Dale, A. & Halgren, E. Automatic parcellation of human cortical 
gyri and sulci using standard anatomical nomenclature. Neuroimage 53, 1-15, 
doi:10.1016/j.neuroimage.2010.06.010 (2010). 
19 Irimia, A. & Van Horn, J. D. The structural, connectomic and network covariance of the 
human brain. Neuroimage 66C, 489-499, doi:10.1016/j.neuroimage.2012.10.066 (2012). 
20 Irimia, A., Chambers, M. C., Torgerson, C. M. & Van Horn, J. D. Circular representation 
of human cortical networks for subject and population-level connectomic visualization. 
Neuroimage 60, 1340-1351, doi:Doi 10.1016/J.Neuroimage.2012.01.107 (2012). 
21 Mayer, E. A. Gut feelings: the emerging biology of gut-brain communication. Nat Rev 
Neurosci 12, 453-466, doi:10.1038/nrn3071 (2011). 
22 Sanmiguel, C. P. et al. Surgically Induced Changes in Gut Microbiome and Hedonic Eating 
as Related to Weight Loss: Preliminary Findings in Obese Women Undergoing Bariatric 
Surgery. Psychosom Med 79, 880-887, doi:10.1097/PSY.0000000000000494 (2017). 
23 Furet, J. P. et al. Differential adaptation of human gut microbiota to bariatric surgery-
induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 
59, 3049-3057, doi:10.2337/db10-0253 (2010). 
24 Remely, M. et al. Gut Microbiota of Obese, Type 2 Diabetic Individuals is Enriched in 
Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus 
anaerobius after Weight Loss. Endocr Metab Immune Disord Drug Targets 16, 99-106, 
doi:10.2174/1871530316666160831093813 (2016). 
25 Macchione, I. G. et al. Akkermansia muciniphila: key player in metabolic and 
gastrointestinal disorders. Eur Rev Med Pharmacol Sci 23, 8075-8083, 
doi:10.26355/eurrev_201909_19024 (2019). 
26 Dao, M. C. et al. Akkermansia muciniphila and improved metabolic health during a dietary 
intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65, 
426-436, doi:10.1136/gutjnl-2014-308778 (2016). 
27 Depommier, C. et al. Supplementation with Akkermansia muciniphila in overweight and 
obese human volunteers: a proof-of-concept exploratory study. Nat Med 25, 1096-1103, 
doi:10.1038/s41591-019-0495-2 (2019). 
28 Liu, H. et al. Butyrate: A Double-Edged Sword for Health? Adv Nutr 9, 21-29, 
doi:10.1093/advances/nmx009 (2018). 
29 Zhang, X. et al. Human gut microbiota changes reveal the progression of glucose 
intolerance. PLoS One 8, e71108, doi:10.1371/journal.pone.0071108 (2013). 
 56 
30 Maya-Lucas, O. et al. The gut microbiome of Mexican children affected by obesity. 
Anaerobe 55, 11-23, doi:10.1016/j.anaerobe.2018.10.009 (2019). 
31 Castaner, O. et al. The Gut Microbiome Profile in Obesity: A Systematic Review. Int J 
Endocrinol 2018, 4095789, doi:10.1155/2018/4095789 (2018). 
32 Kennedy, P. J., Cryan, J. F., Dinan, T. G. & Clarke, G. Kynurenine pathway metabolism 
and the microbiota-gut-brain axis. Neuropharmacology 112, 399-412, 
doi:10.1016/j.neuropharm.2016.07.002 (2017). 
33 Martin, C. R., Osadchiy, V., Kalani, A. & Mayer, E. A. The Brain-Gut-Microbiome Axis. 
Cell Mol Gastroenterol Hepatol 6, 133-148, doi:10.1016/j.jcmgh.2018.04.003 (2018). 
34 Chimerel, C. et al. Bacterial metabolite indole modulates incretin secretion from intestinal 
enteroendocrine L cells. Cell Rep 9, 1202-1208, doi:10.1016/j.celrep.2014.10.032 (2014). 
35 Hwang, I. K. et al. Indole-3-propionic acid attenuates neuronal damage and oxidative stress 
in the ischemic hippocampus. J Neurosci Res 87, 2126-2137, doi:10.1002/jnr.22030 
(2009). 
36 de Mello, V. D. et al. Indolepropionic acid and novel lipid metabolites are associated with 
a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study. Sci Rep 7, 46337, 
doi:10.1038/srep46337 (2017). 
37 Volkow, N. D., Wang, G. J. & Baler, R. D. Reward, dopamine and the control of food 
intake: implications for obesity. Trends Cogn Sci 15, 37-46, doi:10.1016/j.tics.2010.11.001 
(2011). 
38 Wijngaarden, M. A. et al. Obesity is marked by distinct functional connectivity in brain 
networks involved in food reward and salience. Behav Brain Res 287, 127-134, 
doi:10.1016/j.bbr.2015.03.016 (2015). 
39 Sinha, R. Role of addiction and stress neurobiology on food intake and obesity. Biol 
Psychol 131, 5-13, doi:10.1016/j.biopsycho.2017.05.001 (2018). 
40 Nunes-Neto, P. R. et al. Food addiction: Prevalence, psychopathological correlates and 
associations with quality of life in a large sample. J Psychiatr Res 96, 145-152, 
doi:10.1016/j.jpsychires.2017.10.003 (2018). 
 
57 
 
 
 
 
 
 
 
 
 
Chapter 3 
The Intestinal Microbiome Identifies Advanced Fibrosis in Patients with Nonalcoholic Fatty 
Liver Disease 
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INTRODUCTION 
Chronic liver disease is one of the most common medical conditions worldwide that affects 
as many as 840 million people with an estimated rate of mortality of 2 million deaths per year.1 
From 1999 to 2016, deaths from chronic liver disease in the US increased by 65 percent and deaths 
from liver cancer doubled.2 This escalation has been attributed to factors such as increased alcohol 
use in younger Americans, increased intravenous drug use and rapidly rising rates of obesity in 
our society.2  
One of the most challenging aspects of chronic liver disease is the identification of patients 
with liver fibrosis. The development of advanced fibrosis is a major predictor of liver-related 
morbidity and mortality.3-5  Early identification of advanced fibrosis using non-invasive testing is 
a growing area of research in the field of hepatology.4,6,7 The characterization of gut microbial 
biomarkers for advanced fibrosis has been a novel area of ongoing research. For example, Qin and 
colleagues in 2014 reported that an intestinal microbial signature was present in individuals with 
cirrhosis in a Chinese cohort as compared to healthy controls.8 This study included different causes 
of cirrhosis including hepatitis C, hepatitis B, NAFLD, and alcoholic liver disease.  Loomba et al 
in two separate studies was able to identify and validate a distinct microbial signature that was 
related to advanced fibrosis in patients with NAFLD.9,10 However they did not explore other 
etiologies of chronic liver disease, so it is unclear at this time if this signature holds true for other 
causes of liver disease in western society. Given the association of the microbiome with chronic 
liver disease and cirrhosis, the aim of this study was to determine if specific fecal microbial profiles 
can be used as non-invasive biomarkers for advanced fibrosis in patients with varying etiologies 
of chronic liver disease. 
METHODS 
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Patient Recruitment and Stool Collection 
Patients with a diagnosis of chronic liver disease and undergoing ultrasound elastography 
were recruited prospectively from the VA Greater Los Angeles Healthcare System (VA) from 
6/2017 to 6/2018. Chronic liver disease included patients with chronic hepatitis C virus (HCV) 
infection, chronic hepatitis B virus (HBV) infection, liver disease due to chronic alcohol use, 
primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Wilson’s disease, 
autoimmune hepatitis, hemochromatosis, and NAFLD. Patients were excluded if they were treated 
with antibiotics or probiotics within 3 months of enrollment, had only acute liver injury without 
any underlying chronic liver disease, treated HCV infection with sustained virologic response 
without any other forms of chronic liver disease, were on a specialized diet (e.g. gluten free, vegan, 
vegetarian, high protein), had a personal history of GI surgeries, irritable bowel syndrome or 
inflammatory bowel disease. Stool was collected within 7 days of their ultrasound elastography 
and placed into 95% ethanol and stored at -80oC until processing. Patient information including 
age, gender, race/ethnicity, and comorbidities were also collected. For race and ethnicity, there 
were 5 categories with Hispanic as a separate category (i.e. non-Hispanic white, non-Hispanic 
black, Hispanic, Asian, and other). Co-morbidities were collected in order to calculate the Charlson 
comorbidity index, a validated score that assesses overall health and risk of 1-year all-cause 
mortality.11  Stool samples from heathy control patients without any evidence of chronic liver 
disease were also collected. The study was approved by the Veteran’s Affair Greater Los Angeles 
Healthcare System Institutional Review Board. All methods herein were performed in accordance 
with relevant guidelines and regulations. Verbal and written informed consent for study 
participation was obtained from all patients. 
Liver Ultrasound Elastography 
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All patients with chronic liver disease underwent an ultrasound elastography using the FibroScan 
touch 502 machine (Echosens, MA, USA). All ultrasound elastographies were performed by 
trained technicians with over 100 scans of experiences each. Medium (M) and extra-large (XL) 
probes were utilized depending on the patient’s body habitus according to manufacturer’s protocol. 
Controlled attenuation parameter (CAP) score and liver stiffness were collected as non-invasive 
measurements of hepatic steatosis and fibrosis, respectively. All measurements were done at least 
10 times at the same spot with interquartile range/median value less than 30% as per manufacturers 
guidelines.  A CAP score of between 238 and 260 was given a steatosis grade of S1 representing 
11-33% of fatty change in the liver, a score between 260 and 290 was given a grade of S2 
representing 34-66% of fatty change, and a score higher than 290 was given a grade of S3 
representing 67% or more of fatty change as per manufacturer’s guideline. Standard cutoffs of 
liver stiffness as measured in kilopascals based on etiology of liver disease was used to determine 
extent of liver fibrosis (F0/F1 to F4).12 Minimal fibrosis was defined as a score consistent with F0-
F2 and advanced fibrosis was defined as a score consistent with F3-F4, similar to prior published 
studies.10 
16S rRNA Sequencing 
DNA was extracted from ethanol preserved stool using the Powersoil kit as per the manufacturer’s 
instructions (MO BIO, Carlsbad, CA, USA). The V4 region of 16S ribosomal RNA was amplified 
and underwent paired end sequencing on an Illumina HiSeq 2500 (San Diego, CA, USA) as 
previously described.13 The 253 base-pair reads were processed using QIIME 1.9.1 (San Diego, 
CA, USA) with default parameters.14 The average sequence depth per sample was 45,560. 
Operational taxonomic units (OTUs) were picked against the May 2013 version of the Greengenes 
database, prefiltered at 97% identity. After removing OTUs that were present in fewer than 10% 
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of all samples, 1479 OTUs remained for analysis. Raw 16S rRNA sequence data were deposited 
under National Center for Biotechnology Information BioProject PRJNA542724. 
Statistical Analysis 
For demographic data, means are expressed along with their standard deviations and comparisons 
between means were performed using the Student’s t-test. Categorical data were compared using 
the Pearson’s chi-squared test. 
For 16s rRNA sequencing data, alpha diversity metrics that included Chao1 (a metric for species 
richness), Faith’s phylogenetic diversity, and Shannon Index (a metric that incorporates both 
species richness and species evenness) were computed using QIIME. The statistical significance 
of differences in alpha diversity metrics was calculated using a two-tailed t-test. Beta diversity, a 
metric of differences between samples, was calculated using the square root of the Jensen-Shannon 
divergence and visualized by principal coordinates analysis in R.15 Univariate Adonis, a 
permutational analysis of variance, was performed using 10,000 permutations to test for 
differences in the square root of the Jensens-Shannon divergence across the following variables: 
age, gender, race/ethnicity, BMI, control/patient cohort, fibrosis as a binary categorical variable, 
steatosis grade, etiology of liver disease, and Charlson’s comorbidity index. Only variables with a 
p-value <0.1 were used for the final multivariate analysis. This included steatosis grade, Charlson’s 
comorbidity index, and fibrosis. Differential abundance testing was evaluated using DESeq2 in R, 
which employs an empirical Bayesian approach to shrink dispersion and fit non-rarified count data 
to a negative binomial model.16 Variables listed in the multivariate analysis of DESeq2 were the 
same variables listed above for the multivariate Adonis analysis. P-values for differential 
abundance were converted to q-values to correct for multiple hypothesis testing (< 0.05 for 
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significance). All authors had access to the study data and had reviewed and approved the final 
manuscript. 
Random Forests Classifier 
A random forests classifier to predict advanced fibrosis was created in R using the 
randomForest package (https://cran.r-project.org/web/packages/randomForest) with 1001 trees 
and mtry = 2.17 Features inputted into the random forest classifier were those associated 
significantly with advanced fibrosis as determined by multivariate DESeq2 models. The accuracy 
of the random forest classifier was estimated using a 10-fold cross-validation. 
Predicted Metagenomics 
Metagenomic data of each sample was inferred from 16S rRNA sequencing data by using 
PICRUSt 1.1.3 (http://picrust.github.io/picrust), a well validated tool designed to impute 
metagenomic data from 16S rRNA compositional data.18  16S rRNA sequencing data was inputted 
into PICRUSt and normalized by copy number using default parameters. The subsequent 
metagenes were then categorized by function using the KEGG database. Differences in predicted 
metagenes by advanced fibrosis were identified using DESeq2 with p-values adjusted for multiple 
hypothesis testing. 
Validation Cohort 
The findings of the random forest classifier were validated in a separate cohort of NAFLD 
patients recruited at the VA from January 1st, 2019 to October 1st, 2019. Inclusion and exclusion 
criteria were the same as above. All patients underwent stool collection and liver ultrasound 
elastography as described above. Demographic data, race, ethnicity, and comorbidities were 
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collected. In addition, all patients within this cohort filled out a validated diet questionnaire, the 
NIH Diet History Questionnaire III (DHQIII), at the time of their stool collection.19 
RESULTS 
Patient and Healthy Control Characteristics 
Fifty patients with chronic liver disease and 25 healthy controls were recruited. Etiologies for liver 
disease included non-alcoholic liver disease (58.0%), hepatitis C (26.0%), hepatitis B (10.0%), 
and alcohol (6.0%) (Table 1). Nineteen patients had advanced fibrosis and 7/19 (36.8%) had F4 
fibrosis. The healthy control cohort were younger on average than the patients with chronic liver 
disease and comprised of more females (p-value <0.001). The average Charlson’s Comorbidity 
Index for the liver disease cohort was 4.33 + 2.31. There was no difference in Charlson’s 
Comorbidity Index between patients with advanced fibrosis as compared to those without 
advanced fibrosis. There was no difference in race/ethnicity between any groups and there was no 
statistical difference in etiologies of chronic liver disease by fibrosis stage. 
Microbial Profiles Differs by Fibrosis Stage and Etiology of Liver Disease 
In univariate analysis of beta diversity, only 3 variables had a p-value <0.1: steatosis grade, 
Charlson’s comorbidity index, and the presence of advanced fibrosis. Therefore, these variables 
were used for the multivariate analysis. As demonstrated in the principal coordinates analysis plot 
(Figure 1A), the microbial profile of patients with advanced fibrosis differed significantly as 
compared to those with minimal or no fibrosis or healthy controls (p=0.003), while adjusting for 
the other covariates. In regards to alpha diversity metrics, patients with NAFLD and minimal or 
no fibrosis had a lower Chao1 index (species richness) and a lower Faith’s Phylogenetic Diversity 
as compared to healthy controls and NAFLD patients with advanced fibrosis (Figure 1B). There 
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was no statistically significant difference in the Shannon Index (species richness/evenness) in any 
of the group comparisons. 
The average taxonomic composition of chronic liver disease patients divided by etiology 
is summarized in Figure 2A on a phylum and genus level. The composite taxonomic summary of 
all patients with advanced fibrosis, minimal or no fibrosis, or healthy controls is shown in Figure 
2B. Patients with alcoholic liver disease with F0-F2 fibrosis had a higher relative abundance of 
Bacteroidetes than any other group. Examining all patients with advanced fibrosis, there was a 
statistically higher abundance of Prevotella as compared to either healthy control or patients with 
F0-F2 disease as determined by differential abundance analysis adjusting for covariates. 
Differential abundance analysis adjusting for covariates was also performed to compare 
patients with different etiology of liver disease to healthy controls (Figure 3). Because patients 
with alcoholic liver disease and patients with HBV infection only comprised of 8 patients, the 
analysis only focused on patients with chronic HCV infection and NAFLD adjusting for fibrosis 
and the other covariates listed above. Patients with HCV disease as compared to controls differed 
significantly across 25 different OTUs (a taxonomic unit roughly corresponding to species). An 
undefined species belonging to the family Rikenellaceae, two undefined species in the genus 
Bacteroides, and an undefined species in the genus Dialister made up the OTUs with the largest 
relative abundance (Figure 3A). NALFD patients had 34 separate OTUs that were differentially 
abundant from healthy controls (Figure 3B). The species with the highest relative abundance 
included Prevotella copri, an undefined species in the family Ruminococcaceae and an undefined 
species in the family Rikenellaceae. All 3 of these species were underrepresented in patients with 
NAFLD.  Comparing NAFLD to HCV patients, there were 10 OTUs that were differentially 
abundant between the two groups. Prevotella copri, an undefined species belonging to the genus 
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Bacteroides, and an undefined species of the order Clostridiales made three most abundant OTUs. 
Prevotella copri was higher in patients with NAFLD adjusting for fibrosis stage, while the other 
two OTUs were higher in patients with HCV (Figure 3C). 
Between patients with advanced fibrosis vs. minimal or no fibrosis, 26 OTUs were 
differentially abundant. The two most highly abundant differential OTUs were Prevotella copri 
and an undefined species belonging to the genus Bacteroides, both of which were elevated in 
patients with advanced fibrosis (Figure 4A). Examining differences between fibrosis stage within 
patients with HCV and with NAFLD, there were 12 OTUs and 23 OTUs that were differentially 
abundant, respectively. While Prevotella copri did have a higher relative abundance in HCV 
patients with advanced fibrosis, it did not reach statistical significance. Instead, two undefined 
species in the family Ruminococcaceae and Akkermansia muciniphila were the three differential 
OTUs with the highest abundance; all three were elevated in patients with HCV with advanced 
fibrosis (Figure 4B). In NAFLD patients, Prevotella copri was the predominant species and it was 
elevated in patients with advanced fibrosis (Figure 4C). 
Predicted Metagenomic Profile Differs by Fibrosis 
Metagenomic profiles were predicted for each sample from 16S rRNA compositional data 
using PICRUSt. The predicted metagenomic profile that differed between patients with advanced 
fibrosis as compared to those patients with minimal or no fibrosis is summarized in Figure 5. The 
average weighted Nearest Sequenced Taxon Index (NTSI) per sample was 0.08. Low scores 
indicate availability of closely related reference genomes and thus a higher quality of predictions.18 
While there was no overall large difference of the predicted metagenome between samples by 
fibrosis stage as represented by the principal coordinates analysis in Figure 5A (p=0.34), patients 
with advanced fibrosis did have a trend to have more bacterial genes present per sample (Figure 
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5B, p=0.09). From 16S rRNA compositional data, DESEq2 analysis of PICRUSt predicted 
metagenes showed 168 metagenes that were statistically differentially expressed in patients with 
advanced fibrosis as compared to those with minimal or no fibrosis. Categorizing these metagenes 
into functional categories showed 9 pathways that are different between the two groups. The 
pathways that were most different between the two groups were those involved in mineral 
absorption, arachidonic acid metabolism, carbohydrate digestion and absorption, and linoleic acid 
metabolism (Figure 5C). 
A Microbial Signature Predicts Advanced Fibrosis 
Using the 26 OTUs that were differentially abundant between patients with advanced fibrosis and 
patients with minimal or no fibrosis, a random forest classifier was created with high accuracy for 
predicting advanced fibrosis. The area under the receiver operating characteristic curve (AUROC) 
was 0.90 in 10-fold cross-validation (Figure 6A). The contribution of each OTU to the classifier 
was expressed as variable importance score, which measures the decreased accuracy of the 
classifier if that feature was removed (Figure 6B). The species with the greatest variable 
importance score was Prevotella copri followed by two undefined OTUs belonging to the genus 
Lachnobacterium and family Ruminococccaceae. 
A Separate Cohort Validates the Finding that a Distinct Microbial Signature Predicts 
Advanced Fibrosis 
In the validation cohort, there was no statistical difference between patients with advanced 
fibrosis as compared to minimal or no fibrosis in regards to age, gender, comorbidities, race, or 
dietary patterns (Table 2). Similar to the original cohort, a distinct microbial profile exists for 
patients with advanced fibrosis as compared to those with minimal or no fibrosis (Figure 7).  In 
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univariate analysis of beta diversity, only age and advanced fibrosis had a p-value <0.1. Therefore, 
these two variables were used for multivariate analysis. Adjusting for age, the microbial profile of 
patients with advanced fibrosis differed significantly as compared to those with minimal or no 
fibrosis as demonstrated in the principal coordinate analysis plot (p=0.002). There was no 
statistical difference in Shannon index between patients with advanced fibrosis or those with 
minimal to no fibrosis in the validation cohort. 
The average taxonomic composition by fibrosis category is summarized in Figure 7D and 
7E, highlighting increased Prevotella in the advanced fibrosis group. Differential abundance 
testing demonstrated that 7 OTUs differed between patients with advanced fibrosis vs. minimal or 
no fibrosis. Of these, Prevotella copri was the most abundant and it was the only one that was 
enriched in those with advanced fibrosis. Applying the same random forest classifier trained on 
the initial cohort, microbiome composition had an AUROC of 0.82 for differentiating advanced 
vs. minimal or no fibrosis based on 10-fold cross-validation (Figure 7C). 
DISCUSSION 
This study yielded several important findings.  In patients with chronic liver disease, we 
show that those with advanced stages of fibrosis have a distinct microbiome signature compared 
to those with lesser stages of fibrosis.  This held true regardless of etiology of the liver disease and 
after adjusting for other covariates. These differences are characterized by an increase in the genus 
Prevotella and a decrease in Bacteroides. Furthermore, by using these microbial differences, a 
highly accurate model based on stool analysis can be created to identify those with advanced 
fibrosis. 
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We also show that microbial signatures differ across different etiologies of chronic liver 
disease. Similar to prior published works,20,21 chronic HCV infection is associated with a decrease 
in the order Clostridiales and family Ruminococcaceae in patients with advanced fibrosis. This 
study also builds on prior data from NAFLD patients. Within our cohort the most abundant species 
that were significantly different between healthy controls and NAFLD patients while adjusting for 
the level of fibrosis were Prevotella copri, an undefined species in the family Ruminococcaceae, 
and an undefined species in the family Rikenellaceae. This is similar to other prior works showing 
a reduction of Ruminococcus and Prevotella in non-cirrhotic NAFLD patients.9,22 Prevotella’s 
reduction in non-cirrhotic NAFLD patients as compared to healthy controls is likely related to diet. 
Diets that are high in fats and animal protein as compared to diets that are rich in fiber has been 
shown to increase Bacteroides and decrease Prevotella.23,24 This finding is therefore in line with 
previous works that has linked the gut microbiome to diet and non-cirrhotic fatty liver disease. 
Though the idea of using stool as a novel biomarker for advanced fibrosis was recently 
explored and validated, it was only done in patients with NAFLD and did not include other 
etiologies.9 In our cohort of racially diverse patients with varying etiologies of chronic liver 
disease, we show that the idea of using stool analysis to identify patients with advanced fibrosis is 
not only feasible but potentially highly accurate. While several other non-invasive methods are 
currently available for the diagnosis of advanced fibrosis including magnetic resonance 
elastography (MRE), transient elastography, and lab-based models, these modalities can have 
reduced accuracy in patients with diabetes or severe obesity.25,26 Therefore, we propose that stool 
analysis can be a potentially accurate method when other modalities are limited. Combination of 
stool testing with other non-invasive tests including Fib-4 and NAFLD fibrosis scoring may also 
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prove to be an important clinical tool to identify those patients who are more likely to progress to 
advanced fibrosis or cirrhosis. 
In our model, we show that Prevotella copri was the predominant species predictive of 
advanced fibrosis. This was also true in our validation cohort as well. While Prevotella copri is 
still present in normal healthy controls, it is significantly higher in patients with advanced fibrosis, 
a trend that is consistent across all etiologies of chronic liver disease. This is similar to Qin et al 
who showed that Prevotella was enriched in patients with cirrhosis as compared to healthy 
controls.8 Prevotella copri is of great interest as it has been extensively studied in other 
inflammatory diseases.27 It encodes a unique superoxide reductase which may provide resistance 
to or even the use of host-derived reactive oxygen species produced during inflammation.28 Mice 
colonized with P.copri have increased inflammation in a colitis model induced by dextran sulfate 
sodium.29 In vitro models have shown that P. copri can stimulate IL-6, IL-23, and IL-17, all 
cytokines associated with pro-inflammatory Th17 responses.30 This has led many to believe that 
P. copri is a potential driver of inflammation and can even induce such inflammatory diseases as 
rheumatoid arthritis.27 In a recent publication, Prevotella copri was also seen as the main bacteria 
associated with advanced fibrosis in NAFLD pediatric patients.31Our analysis also shows a distinct 
bacterial metagenomic profile for patients with advanced fibrosis. In our analysis, we show that 
the pathways that were most different between patients with advanced fibrosis compared to those 
without were related to mineral absorption, arachidonic acid metabolism, carbohydrate digestion 
and absorption, and linoleic acid metabolism. In mouse models of liver steatosis, linoleic acid was 
shown to be protective against inflammation by affecting PPAR-α and NF-κβ signaling.32  The 
observed associations of P. copri and these functional pathways with advanced fibrosis provide 
preliminary evidence that the gut microbiome may contribute to the progression of liver fibrosis. 
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Therefore, it can be both a useful non-invasive biomarker as well as a potential target for future 
interventions. 
We acknowledge that there were several limitations to this study.  For example, we relied 
on FibroScan rather than liver histology to make the diagnosis of hepatic fibrosis.  With the wide 
adoption of non-invasive testing for fibrosis, the use of liver biopsy is becoming less frequent. 
However, FibroScan is becoming a more widely accepted and accurate method for detecting the 
presence of hepatic fibrosis.26 While other papers have mentioned that obesity might be a limitation 
of FibroScan, our facility and technicians had access to and were familiar with the XL probe, which 
has been proven to have improved diagnostics in obese patients.26 Another limitation is that this is 
a single center VA study and so the generalizability of this study in other settings is still uncertain. 
While the multivariate analyses did not control for all factors that could affect the microbiome, 
including diet and medications, the corroboration of our findings in a separate validation cohort 
that accounted for diet strengthens the findings of our study. Furthermore, while we did attempt to 
represent a wide array of chronic liver disease, the majority of our patients had chronic HCV or 
NAFLD.  A complete representation of all etiologies of chronic liver disease was unable to be 
accomplished due to the rarity of less common etiologies including autoimmune disease, Wilson’s 
disease, hemochromatosis, PSC, PBC, and alpha-1 antitrypsin deficiency. Therefore, future studies 
will be needed in order to confirm that these findings apply to other chronic liver disease etiologies. 
Because this study is cross-sectional, it is unable to establish causality between the gut microbiome 
and hepatic fibrosis. Planned future studies will include the use of fecal metabolomics to examine 
the differential pattern of microbial derived metabolites in patients with advanced fibrosis and the 
use of animal models with microbial transplant or single bacteria gavage to understand the causal 
relationship between the gut microbiome and hepatic fibrosis. 
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In conclusion, there is a distinct microbial signature for patients with advanced fibrosis 
independent of liver disease etiology and other comorbidities. These results suggest that microbial 
profiles can be used as a non-invasive marker for advanced fibrosis and support the hypothesis 
that microbes and their metabolites contribute to hepatic fibrosis. Future studies should focus on 
the mechanism by which these microbial differences may contribute to the progression of fibrosis 
and if the models presented here are valid in other clinical subgroups. 
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Control 
(n=25) F0-F2 (n=31) F3/F4 (n=19) p-value 
Age (yr) (SD) 35.7 (3.5) 58.7 (16.3) 66.2 (6.8) <0.001 
Male (%) (n=62) 52% (n=13) 88.9% (n=28) 100% (n=19) <0.001 
Charlson Comorbidity Index (SD) N/A 3.9 (2.6) 5.1 (1.5) 0.13 
Race/Ethnicity 
Caucasian (%) (n=26) 32.0% (n=8) 38.7% (n=12) 31.6% (n=6) 
0.89 
African American (%) (n=26) 32.0% (n=8) 32.3% (n=10) 42.1% (n=8) 
Hispanic (%) (n=10) 8.0% (n=2) 16.1% (n=5) 15.8% (n=3) 
Asian (%) (n=7) 16.0% (n=4) 6.5% (n=2) 5.3% (n=1) 
Other/Unknown (%) (n=6) 12.0% (n=3) 6.5% (n=2) 5.3% (n=1) 
Etiology of Liver Disease 
EtOH (n=3) 
N/A 
6.5% (n=2) 5.3% (n=1) 
0.18 
HBV (n=5) 12.9% (n=4) 5.3% (n=1) 
HCV (n=13) 16.1% (n=5) 42.1% (n=8) 
NAFLD (n=29) 64.5% (n=20) 47.4% (n=9) 
Table 3-1: Patient and healthy control characteristics. Fibrosis stage labeled from F0-F4. 
Minimal/no fibrosis: F0-F2; Advanced fibrosis: F3/F4; SD: standard deviation; EtOH: Alcohol, 
HBV: Hepatitis B virus, HCV: Hepatitis C virus, NAFLD: nonalcoholic fatty liver disease 
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Validation Cohort F0-F2 (n=27) F3/F4 (n=10) p-value 
Age (yr) (SD) 55.9 (11.0) 60.1 (6.7) 0.27 
Male (%) (n=29) 77.8% (n=21) 80.0% (n=8) 0.63 
Charlson Comorbidity Index (SD) 2.7 (1.3) 2.9 (0.9) 0.99 
Race/Ethnicity 
Caucasian (%) (n=11) 29.6% (n=8) 30.0% (n=3) 
0.23 
African American (%) (n=12) 40.7% (n=11) 0% (n=1) 
Hispanic (%) (n=12) 25.9% (n=7) 50.0% (n=5) 
Asian (%) (n=0) 0% (n=0) 0% (n=0) 
Other/Unknown (%) (n=2) 3.7% (n=1) 10.0% (n=1) 
Dietary Data (intake per day) 
Alcohol (g) 1.81 (2.92) 1.59 (1.73) 0.82 
Protein (g) 83.2 (42.4) 90.2 (44.5) 0.66 
Total fat (g) 79.7 (50.9) 92.7 (63.1) 0.52 
Total saturated fatty acids (g) 25.8 (16.0) 37.1 (33.5) 0.17 
Total monounsaturated fatty acids (g) 29.4 (18.6) 31.4 (18.3) 0.78 
Total polyunsaturated fatty acids (g) 17.4 (13.6) 16.0 (8.3) 0.78 
Cholesterol (mg) 295.6 (197.0) 388.5 (221.0) 0.23 
Carbohydrate (g) 244.9 (169.2) 247.9 (142.3) 0.96 
Total sugars (g) 118.5 (97.0) 129.6 (88.9) 0.75 
Dietary fiber (g) 21.6 (14.1) 20.8 (10.4) 0.87 
Table 3-2: Validation cohort characteristics. SD: standard deviation   
 74 
Figure 3-1: Patients with advanced fibrosis have distinct microbial composition and diversity 
compared to other liver disease patients or healthy controls. A) Beta diversity visualized by 
principal coordinates analysis plot of all patients colored by fibrosis stage or control group. B) 
Alpha diversity metrics by etiology of chronic liver disease and fibrosis stage. Chao1 is a metric 
of species richness, Faith’s Index is a metric of phylogenetic diversity, and Shannon index is a 
metric of species richness/evenness. * represents comparison with p-value <0.05. 
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Figure 3-2: Taxonomic profiles categorized by etiology of chronic liver disease and fibrosis stage. 
A) Taxonomic profiles at the phylum and genus levels, divided by etiology of chronic liver disease 
and fibrosis stage. B) Taxonomic profiles by phylum and genus of patients with advanced fibrosis 
(F3/F4), liver patients with minimal/no fibrosis (F0-F2), and healthy controls. EtOH: Alcohol, 
HBV: Hepatitis B virus, HCV: Hepatitis C virus, NAFLD: nonalcoholic fatty liver disease 
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Figure 3-3: Microbial communities differ by etiology of chronic liver disease. DESEq2 
differential abundance analysis comparing A) HCV patients to control, B) NAFLD patients to 
control, and C) NALFD patients to HCV patients controlling for fibrosis. HCV: Hepatitis C virus, 
NAFLD: nonalcoholic fatty liver disease 
Figure 3-4:  Microbial communities differ by fibrosis stage. DESEq2 differential abundance 
analysis comparing A) advanced fibrosis patients to minimal/no fibrosis patients, B) HCV patients 
with advanced fibrosis (F3/F4) to HCV patients without advanced fibrosis (F0-F2), and C) 
NAFLD patients with advanced fibrosis to NAFLD patients without advanced fibrosis. HCV: 
Hepatitis C virus, NAFLD: nonalcoholic fatty liver disease 
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Figure 3-5: Predicted metagenomic differences by fibrosis stage. A) Principal coordinates analysis 
plot of predicted metagenomic profiles between samples by fibrosis stage. B) Number of predicted 
genes present per sample by fibrosis stage. Solid bar represents the mean and the box represents 1 
standard deviation. *p=0.09. C) Differential abundance analysis (q<0.05) of predicted metagenes 
for advanced fibrosis categorized by KEGG pathways predicted by PICRUSt from 16S rRNA data. 
Figure 3-6: A distinct microbial signature can accurately identify patients with advanced fibrosis. 
A) Receiver operating characteristic curve of the random forests classifier for identifying patients 
with advanced fibrosis. B) Importance scores for features included in the random forests classifier 
for predicting advanced fibrosis. 
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Figure 3-7: Validation of an advanced fibrosis microbial signature in a prospective study of 
NAFLD patients.  A) Principal coordinate analysis plot of beta diversity between patients with 
minimal to no fibrosis (F0-F2) versus patients with advanced fibrosis (F3/F4) within the validation 
cohort. B) Shannon index of the validation cohort between patients with F0-F2 fibrosis and F3/F4 
fibrosis. C) Validation of the random forests classifier as depicted by a receiver operating 
characteristic curve. D-E) Taxonomic profiles by phylum and genus of patients with minimal/no 
fibrosis (F0-F2) and patients with minimal/no fibrosis (F0-F2) within the validation cohort. F) 
DESEq2 differential abundance analysis comparing advanced fibrosis patients to minimal/no 
fibrosis patients in the validation cohort. 
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Chapter 4 
Bariatric Surgery Creates Long-term Changes in the Human Gut Microbiome and Alters the 
Progression of Nonalcoholic Fatty Liver Disease through Natural Killer T-Cell Expression 
  
 83 
INTRODUCTION 
Alongside obesity, the prevalence of nonalcoholic fatty liver disease continues to rise and 
it is estimated to now affect nearly 1 out of every 4 Americans.1 To date, however, there are no 
well-established treatment for nonalcoholic fatty liver disease other than weight loss. While dietary 
interventions are important, many patients have difficulty maintaining a diet long enough in order 
to achieve sufficient weight loss. For that reason, bariatric surgery is one of the few proven 
treatments available for long-term weight loss in patients with obesity.2  Bariatric surgery induces 
changes in the gastrointestinal tract anatomy, physiology and luminal environment, which in turn 
significantly affect the gut microbiome.3,4 Roux-en-Y gastric bypass (RYGB) and laparoscopic 
sleeve gastrectomy (LSG) have similar effects on weight loss, despite the fact that they entail very 
different rearrangements of the GI tract anatomy and physiology.5,6 This may reflect a shared 
mechanism via the gut microbiome, which plays an important role in regulating body weight and 
insulin resistance. Both gastric bypass and sleeve gastrectomy are associated with reduced hunger 
scores and changes in food preferences including a marked reduction in preference for high-calorie 
foods.6 Bariatric surgery is also associated with a marked reduction in cytokines such as 
interleukin-8 and tumor necrosis factor-α (TNF-α).7,8 Several studies performed in mouse models 
have shown that the gut microbiome affects feeding patterns and satiety signaling to the brain.9-11 
To date, the handful of studies in animal models and humans have consistently shown 
changes in microbiota composition after RYGB and LSG, including increased abundance of 
Proteobacteria and decreased Firmicutes.4,12 However, it is still not well understood how these 
shifts in gut microbiota composition contribute to weight loss and improvement in hepatic 
steatosis, inflammation, and fibrosis. 
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One potential pathway that can connect the gut microbiome to fatty liver disease is the host 
innate immune system. While the liver is a key player in lipid metabolism and detoxification, it is 
also an important regulator in host inflammation. The liver is known to house a myriad of immune 
cells including natural killer T-cells, macrophages, lymphoid and other non-lymphoid cells.13 
Being the first organ upstream to the GI tract, the liver is exposed to numerous antigens, pathogens, 
and bacterial signaling molecules. The dysregulation of this cross-talk between the gut, liver, and 
the host immune system has been implicated as a potential driver of insulin resistance and fatty 
liver disease progression.13 
In this study, we will examine the effects bariatric surgery on the gut microbiome in 
humans and host inflammation. We will then explore the causal link between the gut microbiome 
after bariatric surgery on the pathogenesis of nonalcoholic fatty liver disease via the host immune 
system by employing the use of antibiotic-treated mice. 
METHODS 
Patient Recruitment 
The basis of the human data is based on a pre-established cohort of female patients who 
were about to undergo laparoscopic sleeve gastrectomy (LSG). The cohort included only adult 
obese female patients who met clinical criteria for bariatric surgery. Prior to LSG, fecal and blood 
samples were collected before surgery and every 6 months post-surgery up to 1 year.  Fecal and 
blood samples were collected while fasting as well as 30-minutes and 60-minutes post-feeding of 
a standardized 500 calorie meal. Clinical criteria for bariatric surgery were having a BMI > 40, or 
more than 100 pounds overweight, or a BMI > 35 with at least one obesity-related comorbidities, 
including type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, nonalcoholic 
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fatty liver disease, gastric acid reflux, asthma, debilitating arthritis, and severe urinary 
incontinence due to obesity.14 Patients were excluded from the study if they were not deemed a 
good surgical candidate or if they did not consent for blood or fecal sampling. 
16S rRNA Sequencing 
DNA extraction was performed using the ZymoBIOMICS DNA Microprep Kit (Zymo 
Research, Irvine, CA, USA) per the manufacturer’s protocol. PCR amplification of the V4 region 
of the 16S ribosomal RNA gene was followed by a 250x2 paired-end read on an Illumina HiSeq 
(Illumina, San Diego, CA, USA), as previously described.15 The sequences were processed using 
the DADA2 pipeline in R, and SILVA 132 database was used for taxonomy assignment. Next, 
data were incorporated into QIIME 2 version 2019.10. Amplicon sequence variants were filtered 
out if they were not present in at least 15% of all samples. Sequence depths ranged between 4,398 
and 335,645 per sample with a median value of 183,882. 
Metabolomics 
Fecal and serum samples were aliquoted under liquid nitrogen and shipped to Metabolon 
for processing and analysis as a single batch on their global metabolomics and bioinformatics 
platform. Data was curated by mass spectroscopy using established protocols and software as per 
Metabolon. 
Gastrointestinal Hormones and Serum Cytokines 
Plasma levels of gastrointestinal metabolic hormones were measured using a human 
metabolic hormone magnetic assay kit (Millipore) according to the manufacturer's instructions. 
The hormones in the panel included amylin, c-peptide, gastric inhibitory peptide, glucagon-like 
peptide-1 (GLP-1), glucagon, insulin, leptin, peptide YY (PYY), Resistin, ghrelin, and pancreatic 
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polypeptide. Each sample was assayed in duplicate on a 96-well plate. All samples were processed 
in one batch and read via a Luminex 100 reader (Luminex, Austin, TX). Analysis of quality control 
standards provided in the kit matched expectations, and the assay had an inter-assay precision of 
<25% and an intra-assay precision of <7%. A similar assay was done for serum cytokines. The 
panel for serum cytokines included interleukin-6 (IL-6), tumor-necrosis factor alpha (TNF-α), and 
monocyte chemoattractant protein-1 (MCP-1), IL-8, IL-1 beta, hepatocyte growth factor, and 
nerve growth factor. 
Animal Study 
Antibiotic Treatment: Because germ-free animals are born and raised in a germ-free 
environment, their native immune system is innately different than the immune system of wild-
type animals.16 For this reason, antibiotic-treated C57Bl/6 mice and not germ-free C57Bl/6 mice 
were chosen as the model for fecal transplantation. Four human donors (pre- and post-bariatric 
surgery) from the above cohort were selected for fecal transplantation into antibiotic treated mice. 
The donors were selected as each one of them had documented fatty liver disease either by clinical 
notes or by radiology before bariatric surgery that improved after bariatric surgery. Two cocktails 
of antibiotics were used and placed into their drinking water at a concentration of 1 mg/ml per 
antibiotics. The first cocktail was a cocktail that was designed to have minimal systemic absorption 
(non-absorbable) that consisted of ertapenem, neomycin, and vancomycin. The second cocktail 
consisted of antibiotics with higher systemic absorption (systemic) which included ampicillin, 
cefoperazone, and clindamycin. Four-week-old weight-matched mice were treated with a 7-day 
period of non-absorbable antibiotics, followed by a 7-day period of systemic antibiotics, and then 
again by a 7-day period of non-absorbable antibiotics. After each 7-day period, the mice were 
given 2 days of rest with sterile water. This protocol was shown to give stable long-term 
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engraftment of human microbiome samples into mice comparable to germ-free animals.17 After 2 
days of rest after the last cycle of antibiotics, the mice were then gavaged with human fecal samples 
as previously described every other day for a total of three transfers.18 The samples used were 
samples before surgery and samples 6-months post-surgery. A total of 6-10 mice were used per 
fecal sample. Immediately after gavage, the mice were given either a high fat (40% by kcal), high 
fructose (20% by weight), high cholesterol (2% by weight) (HF diet) (Research Diets, 
#D18061301) or a standard diet (10% fat by kcal, 0% fructose, and 0% cholesterol) (Research 
Diets, #D19082701) (SD) for 12 weeks. A negative control group was also present in each food 
group. These group of mice (n=4 each) were gavaged with only media without any fecal material. 
Food was double irradiated and packaged into individual 1-kg bags. A new bag was used at each 
cage change. All mice were housed on a single rack and only one person could change the food, 
water, and bedding of these mice over the 12 weeks to minimize cross-contamination. 
Glucose Tolerance and Body Composition Testing: At the end of the 12 weeks, glucose 
tolerance testing was performed on each mouse by administering 2 grams/kg of glucose 
intraperitoneally and measuring serum glucose via a glucometer (Aimstrip plus, Fisher Scientific) 
at time 0, 30 minutes, 60 minutes, and 90 minutes. Two days after the glucose tolerance testing, 
the mice were then placed into an EchoMRI machine to measure total body fat and lean body mass. 
Tissue and Blood Collection: Portal vein blood was collected by dissecting the portal vein 
and drawing up the blood via a capillary tube (Fischer, catalogue #22260950). Serum was then 
collected via heart puncture. The liver was then collected after perfusing the liver with 15 ml of 
sterile PBS via the inferior vena cava. The GI tract, spleen, gonadal fat, mesenteric fat, and 
dorsolumbar subcutaneous fat were also collected. 
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Cholesterol Testing: Cholesterol assay was performed using a total cholesterol-HDL and 
LDL/VLDL kit as per manufacturer’s protocol (Abcam, catalogue #ab65390). 
Staining and Quantification: Oil red O (Abcam) staining was done on frozen OCT 
embedded tissue as previously described.19 Oil red O quantification was performed by using 
ImageJ and averaging the percent of area stained across 4 liver sections per mice. Hematoxylin 
and eosin staining were performed by the histology core at the University of California, Los 
Angeles. NAFLD activity score based on the hematoxylin and eosin staining was calculated by a 
blinded pathologist for each mice. 
Flow cytometry: Immune cells were isolated from the liver through mechanical disruption 
as previously described.20 Briefly, a section of the liver was pressed through a 70-micron filter into 
freshly prepared RPMI media with 10% fetal bovine serum.  This solution was then wash and 
pelleted at 2000 rpm for 5 minutes at room temperature. The pellet was then placed into a 35% 
Percoll solution with RPMI and centrifuged at 2000 rpm for 20 minutes without any program 
deceleration. The pellet was then resuspended in 15 ml tubes with 3-5 ml of red cell lysis buffer 
for 5 minutes. RPMI with 10% fetal bovine serum was then added and the solution was then 
washed and pelleted again. The pellet was then resuspended with a 1:1 solution of PBS and FACS 
buffer and passed through a 30-micron filter for cell surface staining. Spleen tissue was processed 
similarly except without the Percoll gradient. Cells were first blocked with Fc block for 30 minutes 
at 4 degrees Celsius. The following antibodies were used for cell surface staining: AF488-Ly6C, 
AF647-F4/80, APC/Cy7-CD45.2, BV650-CD3, BV750-CD11b, PE-Nk1.1, PE/Dazzle-NKp46, 
PerCP/Cy5.5-CD4, BV421-CD45R, BV510-CD8a. All antibodies were purchased from 
BioLegend and were used at a dilution of 1:1000. Cells were stained for 30 minutes at 4 degrees 
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Celsius. Flow cytometry was performed on a BD Bioscience LSRII and data was analyzed using 
FlowJo. 
Statistical Analysis 
Human demographic data were expressed as means with standard deviation or as 
percentages. Differences in means were calculated using the Student’s t-test. Differences in 
categorical data was performed using the fisher’s exact test. Sustained weight loss at 1-year was 
defined as having at least a 20% reduction in body weight from baseline. 
Plasma levels of hormones, cytokines, and cholesterol were compared using analysis of 
variance. All p-values were adjusted for false discovery rate. 
Microbiome data was analyzed after sequence variant generation and filtering. Beta 
diversity was calculated using the DEICODE plugin in QIIME2. DEICODE uses a robust 
Aitchison distance metric that has been shown to have higher discriminatory power than other 
metrics such as Bray-Curtis or UniFrac.21 Alpha diversity was also calculated via QIIME2 by using 
the Shannon index (a metric of evenness) with data rarefied to 4397 sequences. The differences in 
beta diversity was calculated using a permutation multivariate analysis of variance via the Adonis 
package in R. Statistical testing for alpha diversity was performed by using analysis of variance. 
Differential abundance testing was evaluated using DESeq2 in R, which employs an empirical 
Bayesian approach to shrink dispersion and fit non-rarified count data to a negative binomial 
model. P-values for differential abundance were converted to q-values to correct for multiple 
hypothesis testing (< 0.05 for significance). 
For metabolomics, the data was normalized by using the scaled imputed data as provided 
by Metabolon. Differential abundance testing was performed using multiple analysis of variance 
corrected for false discovery rate. 
 90 
Correlations between metabolomics, hormone profile, cytokine data, and microbiome analysis 
were performed using spearman’s correlation and corrected for false discovery rate. Correlation 
networks were visualized using Cytoscape (Systems Biology, Seattle). 
RESULTS 
Outcomes After Bariatric Surgery: Eighteen female patients were recruited for the study. The mean 
age was 37.1 + 9.36 years old (Table 4-1). The mean BMI before surgery was 44.7 + 4.9 kg/m2 
and the mean weight before surgery was 118.5 + 18.8 kg. Unsurprisingly, there was a significant 
decrease in both weight and BMI post-surgery as compared to their baseline with an average 
weight loss of 28.8 kg (Figure 4-1). The average patient lost 24.3 + 5.4 % of their body weight at 
6-months and 25.4 + 5.8% at 1-year. In addition to weight loss, patients also had significant 
improvements in regard to their fasting glucose, c-reactive protein (CRP), and lipopolysaccharide 
binding protein (LBP) as compared to baseline (Figure 4-1). Other inflammatory markers such as 
TNF-α and IL-6 were also significantly decreased after bariatric surgery as compared to their 
baseline values (Figure 4-2). There was no significant differences pre- or post-surgery regarding 
MCP-1, IL-8, IL-1 beta, hepatocyte growth factor, and nerve growth factor. The only 
gastrointestinal hormone that had a significant difference after bariatric surgery was leptin (Figure 
4-3), with leptin showing significantly lower levels post-surgery. 
Microbiome Analysis: The gut microbiome of patients pre- and post-surgery differed significantly 
(Figure 4-4A) across time (p-value <0.001) after adjusting for individual variations. There was no 
statistical difference across time in regard to alpha diversity. The taxonomic profiles of patients 
pre- and post-surgery staggered by sustained weight loss at 1-year is summarized in Figure 4-4C. 
Because most of the weight loss occurred at 6-months, we focused our analysis by comparing 
samples from 6-months post-surgery to baseline values. In patients that did not achieve sustained 
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weight loss (i.e. non-responders), a group belonging to Ruminococcus was overrepresented and a 
group belonging to Lachnospiraceae was underrepresented in patients 6-months post-surgery as 
compared to baseline. Conversely, in patients that did have sustained weight loss (i.e. responders), 
Sutterella and Streptococcus were overrepresented at 6-months. Similar to the non-responders, a 
group belonging to Lachnospiraceae family was underrepresented (Figure 4-4D). 
Metabolomics Profiles Changed After Surgery: Forty-six serum metabolites were significantly 
different between the three different time points as determined by DESEq2: Pre-surgery, 6-months 
post-surgery, and 1-year post-surgery. These metabolites are summarized in Figure 4-5. Thirty-
one of these metabolites belong to pathways involving lipid metabolism. 
Baseline Microbiome Profile Predicts Sustained Weight Loss After Bariatric Surgery: While there 
was a significant difference in the gut microbiome of patients across time, there was also a 
significant difference when you examined the baseline gut microbiome of patients who had 
sustained weight loss and those that did not (Figure 4-6) (p-value=0.018). There was no difference 
in alpha diversity between these two groups. DESEq2 analysis shows that patients with sustained 
weight loss had 18 bacterial taxa that were overrepresented and 18 bacterial taxa that were 
underrepresented as compared to those without sustained weight loss. Of the 18 bacterial taxa that 
were overrepresented, Blautia caecimuris, Parabacteroides distasonis, and Bacteroides vulgatus 
were the three taxa with the highest relative abundance. Of the 18 bacterial taxa that were 
underrepresented, Alistipes obesi, Ruminococcaceae UCG-002, Phascolarctobacterium 
succinatutens, Alistipes ihumii, and Lachnospiraceae NK4A136 group were the taxa with the 
highest relative abundance. By using a random forest classifier, the microbiome had an area under 
the receiver operator curve (AUROC) of 0.98. The classifier that was based on microbiome data 
had the highest accuracy at predicting sustained weight loss at 1-year as compared to a classifier 
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based solely on baseline fasting hormone data (AUROC 0.68), baseline cytokine data (AUROC 
0.61), and demographic information (AUROC 0.55). Lachnospiraceae NK4A136 group was the 
taxa with the greatest importance value in the classifier. A correlation network between microbial 
data and serum metabolite and hormones is summarized in Figure 4-7. 
Microbial Transplant from Patients Pre- and Post-Bariatric Surgery Induces Significant Weight 
Changes in Antibiotic-Treated Mice: Not surprisingly, mice fed on a HFHF diet had significantly 
higher weight gain than mice fed on a SD. However, mice that were transplanted with the fecal 
microbiome of patients before bariatric surgery gained significantly more weight both on a SD and 
a HFHF diet as compared to mice that were transplanted with fecal material from the same patient 
post-surgery (Figure 4-8). This weight gain was not associated with any significant changes in 
cumulative food intake over the same period. Consistent with the weight gain, EchoMRI results 
showed that the mice on a HFHF diet had a significantly higher percentage of body fat and a lower 
percentage of lean body mass. Mice that were transplanted with the fecal microbiome of patients 
before bariatric surgery had significantly higher body fat and lower mean body mass a SD and a 
HFHF diet as compared to mice that were transplanted with fecal material from the same patient 
post-surgery. Mice fed on a HFHF diet also had higher liver mass as compared to those with SD. 
There was no significant difference in liver weights of any group while on a SD, but while on a 
HFHF diet, the mice with pre-bariatric microbiome had significantly heavier livers than the mice 
with post-bariatric microbiome. 
Microbial Transplant from Patients Pre- and Post-Bariatric Surgery Alters Insulin 
Resistance and Cholesterol: Mice who were fed on a HFHF diet, had significantly worse glucose 
tolerance than the mice on a SD. In line with the human study, the mice with pre-bariatric 
microbiome had worse glucose tolerance than the mice with post-bariatric microbiome. This 
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difference, however, only occurred on the SD and not on the HFHF diet (Figure 4-9). This was 
similar to the results with cholesterol. Mice who were fed on a HFHF diet, had significantly higher 
cholesterol levels than the mice on a SD. The mice with pre-bariatric microbiome had higher levels 
of total cholesterol and higher levels of LDL/VLDL than the mice with post-bariatric microbiome. 
This difference, however, only occurred on the SD and not on the HFHF diet. 
Microbial Transplant from Patients Pre- and Post-Bariatric Surgery Significantly Altered 
the Progression of Nonalcoholic Fatty Liver Disease: Mice on a HFHF diet had significantly worse 
steatosis (Figure 4-10) as determined by oil red o staining as well by NAFLD activity score 
(Figure 4-11). The mice with pre-bariatric microbiome had worse steatosis both on a SD and a 
HFHF diet as compared to their pos-bariatric counterparts. These mice also had worse NAFLD 
activity score both on a SD and a HFHF diet, but it only reached significance while on a HFHF 
diet. 
The Microbial Differences Present in Pre- and Post-Bariatric Surgery Significantly Alters 
the Immunophenotype of the Liver: A HFHF diet significantly decreases the levels of NKT cells 
within the liver as compared to a SD alone (Figure 4-12). Furthermore, the microbiome of pre-
bariatric surgery patients significantly lowers the expression levels of NKT cells in the liver as 
compared to their post-bariatric counterparts. This was seen in both on a SD as well as a HFHF 
diet. The microbiome of pre-bariatric surgery patients also significantly increases the expression 
levels of CD8+ CD4- T cells in the liver as compared to their post-bariatric counterparts both on 
a SD and a HFHF diet. A HFHF diet also significantly increases the expression level of Kupffer 
(CD11b (intermediate +) F4/80+) cells in the liver as well the levels of monocyte-derived 
macrophages (CD11b (High +) F4/80 +) (Figure 4-13). While a HFHF diet increased the levels 
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of these immune cells, the microbiome of post-bariatric patients was able to decrease them both, 
though this was only seen in the HFHF diet. 
DISCUSSION 
Bariatric surgery remains one of the best long-term treatment for obesity. Similar to prior published 
data, bariatric surgery provides long-term weight loss and reduces the pro-inflammatory state that 
is associated with obesity.22 In our study we show that patients who undergo laparoscopic sleeve 
gastrectomy was able to achieve on average 25.4% of total body weight loss at 1-year. This was 
associated with a decrease in CRP, LBP, TNF-α, and IL-6. The likely decrease in these 
inflammatory markers is most likely due to a decrease in adipose tissue. Previous studies 
examining adipose tissue have shown that IL-6 and TNF-α expression is higher in adipose tissue 
of obese patients as compared to lean adipose tissue.23,24 In other prospective studies examining 
bariatric surgery, researchers have found that with bariatric surgery and a decrease in adiposity IL-
6 and TNF-α decreases both in the serum as well as in the adipose tissue.22  Severe obesity is also 
marked by severe insulin resistance and leptin resistance.25 Here we show that with a reduction in 
weight as caused by bariatric surgery, insulin resistance is improved and basal leptin levels are 
lowered. 
While laparoscopic sleeve gastrectomy may not alter the GI tract as much as a Roux-en-Y gastric 
bypass, it is still able to cause significant long-term shifts in the gut microbiome. In our study we 
see that patients that did not meet the criteria for sustained weight loss, had less Lachnospiracea 
than at baseline and patients that had sustained weight loss had less Lachnospiraceae and more 
Sutterella and Streptococcus than at baseline. We also see a trend of increasing Bacteroides over 
time in the patients with sustained weight loss. In studies examining the gut microbiome and 
obesity, both Bacteroides and Sutterella have been shown to be negatively associated with obesity, 
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while bacteria like Lachnospira have been positively associated with obesity.26,27 Therefore, the 
reduction of Lachnospiraceae over time with an increase in Bacteroides and Sutterella are within 
line with previously published microbial data. The exact mechanism by which the gut microbiome 
can cause obesity is still an active area of research. It is likely multifactorial that includes bile acid 
modulation, farnesoid X receptor signaling, alterations in the brain-gut axis, and increase energy 
extraction.28-30 
However, a novel area by which the gut microbiome is gaining traction is in its role as a potential 
biomarker. Here we show that gut microbiome at baseline is an extremely accurate biomarker at 
predicting sustained weight loss of at least 20% body weight at 1-year post-bariatric surgery. We 
see that patients who are likely going to have sustained weight loss as compared to those that are 
not have very distinct gut microbiome at baseline. At baseline, those that had a better response to 
bariatric surgery had higher levels of Bacteroides and Parabacteroides and lower levels of 
Alistipes. Both Bacteroides and Parabacteroides have been shown to be anti-inflammatory by being 
able to promote regulatory T-cells and IL-10.31,32 Conversely, Alistipes has been shown to be 
associated with type 2 diabetes.33 The high accuracy of the gut microbiome to predict response to 
bariatric surgery suggests the idea that a person’s innate microbiome can potentially enhance the 
effect seen by bariatric surgery. This suggests that the gut microbiome may be used as a potential 
biomarker for success with bariatric surgery. But it also suggests that the gut microbiome could be 
potentially altered before surgery as a method to increase the effectiveness of bariatric surgery. 
Future interventional trials will be needed to test this hypothesis. 
We then showed the causal link between the gut microbiome with obesity and nonalcoholic fatty 
liver disease by transplanting the microbiome of 4 donors before and after their surgery into 
antibiotic treated mice. The results clearly show that the microbiome of patients before bariatric 
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surgery was able to increase the weight and body fat as compared to the microbiome after surgery. 
These changes were also associated with worse nonalcoholic fatty liver disease, worse insulin 
resistance, and worse cholesterol profile. In a landmark paper by Tremaroli et al they showed 
similar results of weight gain in germ-free mice transplanted with pre-bariatric microbiome and 
weight loss in germ-free mice transplanted with post-bariatric microbiome while on a standard 
diet.34 In their study, there was no difference in food intake, respiratory quotient, or activity level 
in mice transplanted with control microbiome versus those transplanted with post-laparoscopic 
sleeve gastrectomy microbiome.34 Our study corroborates that finding. Therefore, without changes 
in food intake or energy expenditure to explain the differences in weight gain, we propose that the 
differences are due to changes in energy extraction between the two microbiome populations. This 
idea is corroborated by the finding that the microbiome of pre-bariatric surgery patients and obese 
patients have a higher capacity to extract energy from the diet as evident from an increase 
concentration of fecal short chain fatty acids.34,35 Furthermore differences in the microbiome can 
also lead to differences in bile acid concentration. Previous studies have shown that leaner 
phenotypes and patients who have undergone bariatric surgery have higher levels of bile acids.34 
These bile acids in turn can bind to such receptors like the Farnsenoid X receptor (FXR), which 
has been of great interest lately with the introduction of obeticholic acid (an FXR agonist) for the 
potential treatment for NAFLD.36 We postulate that these differences in energy extraction and bile 
acid composition are contributing factors to the differences in weight seen in mice transplanted 
with pre-bariatric microbiome versus those transplanted with post-bariatric microbiome. 
However, NAFLD is not merely a disease of increase fat. It is a disease that often requires multiple 
hits that usually involves increased inflammation.37 Many studies to date have shown that an obese 
microbiome is often associated with increased gut permeability.38,39 This “leaky gut” can lead to 
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increased bacterial translocation and antigen presentation in the gut as well as in the portal 
circulation leading to the liver.39 This is one of the few studies that have looked into the connection 
between the gut microbiome and the immune system of the liver. Here we show that pre-bariatric 
surgery microbiome leads to an increase in adiposity in the liver and a significant decrease in NKT 
cells and an increase in cytotoxic T cells, Kupffer cells, and monocyte derived macrophages. This 
is in line with several other studies that have examined the immune system of the liver in regards 
to NAFLD.40 In animal models of obesity, CD8+ T cells are often increased in visceral adipose 
tissue and may even proceed the infiltration of inflammatory macrophages.41 In liver disease, 
cytotoxic T-cells are categorized as proinflammatory and their activation is often a hallmark of the 
progression from bland steatosis to steatohepatitis.40 The pro-inflammatory state of the pre-
bariatric microbiome is further exemplified by the increase level of Kupffer cells and monocyte-
derived macrophages in the liver. One potential mechanism that can link the gut microbiome to 
the activation of Kupffer cells is toll-like receptor (TLR) signaling. TLR are part of a family of 
pattern recognition receptors that recognize bacterial, viral, and fungal ligands.42 TLR can be 
activated by LPS and this activation can lead to an increase in nuclear factor κβ and Kupffer cell 
activation.43 Furthermore, Kupffer cells can directly lead to the depletion of NKT cells via IL-12 
expression.44 The reduction of NKT cells in the liver of mice transplanted with pre-bariatric 
microbiome is in line with several obesity-related animal models.40 NKT cells almost exclusively 
respond to lipid antigens and can be both proinflammatory or anti-inflammatory in nature.44 In 
previous studies regarding both humans and mice, NKT cells are often depleted in favor of pro-
inflammatory macrophages.45 Many other studies have shown that NKT cells can have an 
attenuating effect on the development of NAFLD by both reducing steatosis as well as 
inflammation.40,45,46 Future studies are needed to examine if these effects on the immune system 
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of the liver are mediated by increase adiposity or mediated by increase inflammatory signaling 
from the gut microbiome or both. 
Our study shows that the gut microbiome is a critical player in the development and progression 
of obesity and NAFLD. The gut microbiome at baseline highly predicts the level of response to 
bariatric surgery and that the changes in the gut microbiome via bariatric surgery is sufficient to 
induce changes in steatosis and inflammation in the liver irrespective of diet. This implies that 
targeting either the gut microbiome or its downstream effects is a feasible and valid method for 
the treatment of both obesity and NAFLD. 
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Average (SD) (n=18) Pre-Surgery Post-Surgery (6 mo) P-value 
Age (yr) 37.1 (9.36) 37.1 (9.36) NA 
BMI 44.7 (4.9) 33.9 (4.8) <0.001 
Weight (kg) 118.5 (18.8) 89.7 (16.9) <0.001 
Race/Ethnicity 
Non-Hispanic White (%) 44.4 
 NA 
African American (%) 5.6 
Asian (%) 11.1 
Hispanic (%) 38.9 
Table 4-1: Patient characteristics before and after bariatric surgery 
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Figure 4-1: Bariatric surgery leads to significant weight loss, improved insulin resistance, and 
reduce inflammation. Weight change before and after bariatric surgery by (A) absolute weights, 
(B) percent weight loss from baseline and (C) BMI. Sustained weight loss was defined as at least 
20% weight loss at 1-year post surgery. D) Fasting glucose before and after surgery. E) C-reactive 
protein (CRP) serum levels before and after surgery. F) Lipopolysaccharide binding protein (LBP) 
serum levels before and after surgery. *Signifies p-values <0.05. 
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Figure 4-2: Inflammatory cytokine are reduced after surgery. A) Tumor necrosis factor (TNF) 
alpha and (B) IL-6 serum levels before and after surgery. *Signifies p-values <0.05. 
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Figure 4-3: Leptin resistance decreases after bariatric surgery. A) Serum leptin levels before and 
after surgery as measured while fasting (-30) and post-prandially starting at 0 min time point. B) 
Area under the curve (AUC) for the graph. *Signifies p-values <0.05. 
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Figure 4-4: Microbiome is altered by bariatric surgery. A) Prinicipal coordinate plot colored by 
sustained weight loss with lines connecting patient samples across time. B) Alpha diversity as 
measured by Shannon Index which measures species evenness and abundance. C) Taxonomic plots 
by sustained weight loss over time. D) DESEq2 analysis showing taxa that are differentially 
abundant at 6 months as compared to baseline in patients with sustained weight loss (Responder) 
and those without sustained weight loss (Nonresponder). 
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Figure 4-5: Heat map of differentially abundant serum metabolites as determined by DESEq2 
across time. 
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Figure 4-6: Baseline microbiome predicts sustained weight loss at 1-year post-bariatric surgery. 
A) Principal coordinate plot of the gut microbiome at baseline colored by patients achieving 
sustained weight loss. B) Alpha diversity as measured by Shannon Index which measures species 
evenness and abundance. C) Taxonomic plots by sustained weight loss D) DESEq2 analysis 
showing taxa that are differentially abundant between those with sustained weight loss and those 
without. Only those with a relative abundance of >0.0006 are shown. E) Receiver operator curves 
for random forrest classifier for classifier based on microbiome data, fasting hormone data, 
cytokine data, and demographic data. F) Variable importance plot of microbial random forest 
classifier. 
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Figure 4-7: Correlation network of bacterial taxa to serum metabolite and serum hormone. Red 
color indicates a negative correlation. Blue indicates a positive correlation. 
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Figure 4-8: The gut microbiome of patients pre-bariatric surgery causes significant weight gain 
while on a standard diet (SD) or a high fat, high fructose, high cholesterol (HFHF) diet. Weight 
change over time of mice transplanted with pre- or post-bariatric surgery microbiome or mice 
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given negative control on a (A) SD or (B) HFHF diet. Cumulative food intake of the different mice 
on a (C) SD or (D) HFHF diet. EchoMRI results of mice as measured by (E) percent body fat or 
by (F) percent lean body mass. Liver weight of the different groups on a (G) SD or (H) HFHF diet. 
*Signifies p-value <0.05. 
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Figure 4-9: The gut microbiome of patients pre-bariatric surgery causes significant changes in 
insulin resistance and cholesterol while on a standard diet (SD) or a high fat, high fructose, high 
cholesterol (HFHF) diet. Glucose tolerance testing (GTT) of the different mouse groups on a (A) 
SD or (B) HFHF diet. (C-D) Area under the curve (AUC) of the respective graphs in A and B. 
Serum cholesterol level of the different mouse groups on a (E) SD or (F) HFHF diet. *Signifies p-
value <0.05. 
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Figure 4-10: The gut microbiome of patients pre-bariatric surgery causes significant steatosis in 
the liver of mice on both a standard diet (SD) or a high-fat, high-fructose, high-cholesterol (HFHF) 
diet. Oil red o staining of liver tissue of mice transplanted with pre-bariatric surgery microbiome 
or post-surgery microbiome on a (A) SD or a (C) HFHF diet. B,D) is the percent of oil red o (ORO) 
staining. *Signifies p-values <0.05. 
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Figure 4-11: The gut microbiome of patients pre-bariatric surgery causes significant nonalcoholic 
steatohepatitis as measured by the NAFLD Activity Score on both a standard diet (SD) or a high-
fat, high-fructose, high-cholesterol (HFHF) diet. Hematoxylin and Eosin staining of liver tissue of 
mice transplanted with pre-bariatric surgery microbiome or post-surgery microbiome on a (A) SD 
or a (C) HFHF diet. B,D) is their respective NAFLD activity score colored by the different sections 
that make up the score: steatosis, inflammation, ballooning. *Signifies p-values <0.05. 
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Figure 4-12:  The gut microbiome of patients pre-bariatric surgery reduces natural killer T (NKT)-
cell and increases CD8+ T-cells in the liver. A-D) Representative flow cytometry plots of CD4 
and NK1.1 gated from CD3+B220- population. E) Graph showing percent of NKT cells as a 
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percentage of CD45.2+ cells across the different groups. F-I) Representative flow cytometry plots 
of CD4 and CD8 gated from CD3+B220- population. J) Graph showing percent of CD8+ T-cells 
as a percentage of CD45.2+ cells across the different groups.  *Signifies p-value<0.05.  
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Figure 4-13: The gut microbiome of patients pre-bariatric surgery increases kupffer cells and 
monocyte-derived macrophages in the liver. A-D) Representative flow cytometry plots of CD11b 
and F4/80 gated from CD45.2+ Macrophage population. E) Graph showing percent of Kupffer 
cells as a percentage of CD45.2+ cells across the different groups. F-I) Representative flow 
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cytometry plots of CD11b and F4/80 gated from CD45.2+ Macrophage population. J) Graph 
showing percent of monocyte-derived macrophages as a percentage of CD45.2+ cells across the 
different groups.  *Signifies p-value<0.05. 
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 In these series of studies, we have shown that the gut microbiome is a highly accurate 
predictor for several stages of obesity and NAFLD. Many studies before have shown that the gut 
microbiome of obese individuals is very distinct from those with leaner phenotype.1-3 In our study 
we show for the first time how the gut microbiome may also be distinct in patients with specific 
eating disorders. We show that the gut microbiome is part of a classifier that is highly accurate at 
predicting food addiction in obese individuals. This particular microbiome profile is characterized 
by an underrepresentation of Bacteroides, Akkermansia, and Eubacterium, with an 
overrepresentation of Megamonas. Furthermore, the dysbiosis of the gut microbiome is associated 
with a significant decrease in a tryptophan-related metabolite, indolepropionate. This metabolite, 
as mentioned earlier has been implicated as being neuroprotective by potentially reducing 
antioxidants, DNA damage, and the production of β-amyloid fibrils.4 These changes noted in the 
microbiome and fecal metabolite profile was associated to an increased connectivity between two 
regions of the brain’s extended reward network, suggesting that these alterations in the brain-gut-
microbiome axis may be important to the sometimes maladaptive eating behaviors of obese 
individuals.  
 Furthermore, research has shown that the microbiome and metabolite profile of patients 
with NAFLD differs at each stage of the disease, from bland steatosis to advanced fibrosis. By 
using a novel approach that incorporated machine learning, we were able to create and validate a 
classifier that was highly accurate at identifying NAFLD patients with advanced fibrosis. The main 
bacteria that was the most important in the classifier was Prevotella copri. The prevalence of this 
inflammatory bacteria in patients with advanced fibrosis suggests that it may play a role in the 
progression from steatosis to steatohepatitis and fibrosis through the production of reactive oxygen 
species.  
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 We explored this causal link of the gut microbiome in fatty liver disease by utilizing an 
antibiotic-treated mouse model of microbial transplantation. In the human data set, we show that 
bariatric surgery induces long-term changes in the gut microbiome. We also show that the baseline 
gut microbiome of patients before surgery highly predicts their level of response to bariatric 
surgery. By taking the microbiome of these patients and transplanting them into antibiotic-treated 
mice we show a causal relationship between the gut microbiome to obesity and NAFLD. We show 
that the microbiome of patients before bariatric surgery is able to induce significant weight gain 
that is accompanied with significant steatosis and inflammation in the liver. We propose that 
through a combination of increased intestinal permeability and antigen presentation to the portal 
vein, along with increase inflammatory signaling, the gut microbiome can cause the shift that 
occurs from NAFL to NASH. 
Overall, it is clear that obese individuals have a very distinct microbiome from lean 
individuals, and this difference is sufficient enough to induce weight, metabolic, and inflammatory 
changes in the host. Our studies have shown that the microbiome can be used accurately as a 
noninvasive biomarker for early detection of patients with NAFLD. The data also suggests that 
the signaling pathways related to the gut microbiome can be used to generate novel therapeutics 
against NAFLD and potentially fibrosis. Future studies will include the analysis of the portal 
venous metabolite of the antibiotic-treated animal model as well as serum and adipocyte hormone 
and cytokine levels. If a metabolite is found that correlates to the findings of NASH in the liver, 
future studies will involve analyzing its potential effects and signaling pathways.  
 We are just beginning to understand the role of the gut microbiome in health and disease. 
Through advances in sequencing technology and better animal modeling, a microbial-based 
therapy for obesity and NAFLD is potentially on the horizon.  
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